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Acute heart failure (AHF) is one of the leading causes of hospitalization and death worldwide. More than one million 
people in the United States and Europe, and more than 200,000 people in Japan are hospitalized each year. AHF-
associated mortality is unsatisfactory high, and there is no specific treatment that has been shown to improve 
prognosis. Although the pathophysiological background of AHF is multifactorial, renal dysfunction is among one of 
the most common and powerful prognostic factors. The overwhelming amount of data related to the prognostic 
importance of renal function and worsening renal function in patients with heart failure was summarized in a recent 
meta-analysis. In this meta-analysis, it was reported that 49% of patients with heart failure had concomitant renal 
dysfunction, which is typically defined as an estimated glomerular filtration rate (GFR) < 60 mL/min/1.73 m2. 
Worsening renal function was present in 23% of patients. Moderate renal dysfunction (hazard ratio 1.59, 95% 
confidence interval [CI] 1.49-1.69), severe renal function (hazard ratio 2.17, 95% CI 1.95-2.40), and worsening renal 
function (hazard ratio 1.95, 95% CI 1.45-2.62) were independently associated with mortality. These findings imply 
the prognostic importance of renal function in patients with heart failure.  
 
Despite the presence of such detailed prognostic information, surprisingly little is known regarding the 
pathophysiological mechanism and treatment of unfavorable heart-kidney interplay in patients with AHF. Renal 
dysfunction in patients with heart failure has been believed to be associated more with cardiac output or ejection 
fraction than congestion. Many recent studies, however, imply there is no or very weak, if any, association between 
cardiac output and renal function, and venous congestion might be a more prominent driver of renal dysfunction 
in patients with heart failure. Some studies, which have tested an association between changes in serum creatinine 
and prognosis in patients with AHF, showed that an increase in creatinine does not always lead to a worse prognosis, 
and should be interpreted in the context of the clinical course. Moreover, many studies have shown that not only 
glomerular but also tubular function is impaired and independently contribute to the unfavorable association 
between renal dysfunction in general and worse outcomes. Nevertheless, the terms “renal function” and 
“(estimated) GFR” are often used interchangeably. It is well known that creatinine has important limitations, even 
as a biomarker of glomerular function. Creatinine is influenced by some non-renal factors including muscle mass, 
diet, and ethnicity, and there is a non-negligible discrepancy between GFR estimated from serum creatinine levels 
and true GFR in patients with heart failure. Also, because creatinine does not rise until GFR decreases by 50% and 
does not show dynamic changes with GFR, it is not an ideal biomarker to monitor (acute) changes in glomerular 
function. One of the factors that hampers further intensive clinical research aimed at revealing this complex 
association is a lack of renal biomarkers to better encompass and reflect the underlying pathophysiological 
background of renal function. Because the absolute value and serial changes of serum creatinine or eGFR do not 
contain any information on pathophysiological background, it is not plausible to design the study using creatinine 
as an outcome measure alone. Furthermore, several randomized clinical trials that tested drug targeting in AHF 
patients with concomitant renal dysfunction showed neutral results in terms of prognosis, and many questions 
remain unanswered. It is undisputable that there is a need for novel renal biomarkers to better understand this 
multifactorial and complex, but clinically relevant heart-kidney interaction in patients with AHF.  
 
The kidney is not the only organ impaired in patients with AHF, and several recent studies showed that many other 
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organs, including liver, bone marrow, brain, intestine, and lung are also implicated in unfavorable organ cross-talk. 
Not surprisingly, outcome is more negatively impacted when increasingly more organs are impaired. Congestion is 
one of main players in the pathophysiological background of AHF, and is also one of the main drivers of organ 
dysfunction in patients with AHF. For instance, venous or systemic congestion can lead to increased ventricular wall 
stress, myocardial stretch, and subsequent myocardial necrosis, which can be detected using cardiac troponin. 
Hepatic dysfunction is associated with heart failure due to increased venous pressure and reduced hepatic blood 
flow leading to elevated cholestatic enzymes, transaminases, and bilirubin. Of note, a biomarker sub-study, RELAX-
AHF, showed that the prognosis in organ damage over time in AHF together with the degree of each organ 
dysfunction can affect future prognosis. According to these findings, it could be hypothesized that early 
decongestion might prevent further damage to organs. Indeed, the concept of early treatment in patients with AHF 
has been launched in the latest Heart Failure Guidelines of the European Society of Cardiology in 2016. However, 
recently performed clinical trials have focused more on the intervention itself and less on the time to intervention. 
Based on this review of the current literature and the gaps identified therein, testing the hypothesis that providing 
effective decongestion treatment at appropriate times as a key to improving outcomes of AHF patients is of 
particular interest from a clinical and scientific perspective.  
 
Aims of this thesis 
Although many novel renal biomarkers have been tested and shown to be associated with prognosis in patients 
with heart failure, very few of them were associated with pathophysiological background of cardio-renal interaction 
in heart failure. In the first part of this thesis, I aim to evaluate a novel renal biomarker and pre-existing metric of 
renal function to identify its role and explore the possibility that they might provide us with pathophysiological and 
prognostic information which cannot be achieved by pre-existing biomarkers. Chapter 2 examines the position of 
the novel cardio-renal biomarker, proenkephalin, in patients with heart failure. Chapter 3 defines the normal range 
of the blood urea nitrogen-creatinine ratio using the general population, and identifies the prognostic implication 
of the blood urea nitrogen-to-creatinine ratio in patients with acute heart failure.  
In the next part of this thesis, I test the hypothesis that early treatment with a novel diuretic could be an option for 
patients with acute heart failure with concomitant renal dysfunction. Although renal dysfunction is one of the 
comorbidities which relate to poor treatment response and outcomes in patients with AHF, specific treatment for 
this high-risk subgroup has yet to be developed. Chapter 4 describes the rationale and design and Chapter 5 
summarizes the results of the clinical utilities of early treatment with vasopressin-2 receptor antagonists in patients 
with AHF with concomitant renal dysfunction in a randomized clinical trial (AQUAMARINE study). Chapter 6 
investigates the effects of an early adjunctive therapy with tolvaptan on the diuretic response in AHF patients with 
renal dysfunction.  
In Chapter 7, we aim to study the effects of early loop diuretic therapy on short-term prognosis in patients with 
AHF. Although the idea “early treatment provides better prognosis” has been around for a long time in AHF, no 
study adequately and specifically tested this hypothesis. 
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Proenkephalin (pro-ENK) has emerged as a novel biomarker associated with both renal function and cardiac 
function. However, its clinical and prognostic value have not been well evaluated in symptomatic heart failure 
patients.  
 
Methods and Results 
The association between pro-ENK and markers of renal function was evaluated in 95 chronic heart failure patients 
who underwent renal hemodynamic measurements including renal blood flow (RBF) and glomerular filtration rate 
(GFR) using131I-Hippuran and 125I-Iothalamate clearances, respectively. The association between pro-ENK and 
clinical outcome in acute heart failure was assessed in another 1589 patients. Pro-ENK was strongly correlated with 
both RBF (P<0.001) and GFR (P<0.001), but not with renal tubular markers. In the acute heart failure cohort, pro-
ENK was a predictor of death through 180 days, heart failure rehospitalization through 60 days, and death or 
cardiovascular or renal rehospitalization through day 60 in univariable analyses, but its predictive value was lost in 
a multivariable model, when other renal markers were entered in the model.  
 
Conclusions  
In patients with chronic and acute heart failure, pro-ENK is strongly associated with glomerular function, but not 
with tubular damage. Pro-ENK provides limited prognostic information in acute heart failure patients on top of 





Renal dysfunction is frequently observed in heart failure patients1, and both baseline renal function and worsening 
of renal function accompanying inadequate decongestion during hospitalization is associated with prolonged 
hospitalization, rehospitalization, and death2, 3.  
Enkephalins including pro-enkephalin (pro-ENK) are small endogenous opioid peptides encoded by the 
proenkephalin gene, and have been shown to be implicated in neurotransmission, autocrine and paracrine function, 
and cardiac function. Most of the early studies have focused on its role in neuronal tissues, but it is also suggested 
to be produced and act in non-neural tissues including heart and kidney4. Due to the instability of enkephalins, a 
stable fragment of their precursor, termed pro-ENK, has been devised as stable and reliable surrogate plasma 
marker5. In patients with acute kidney injury after cardiac surgery, pro-ENK was shown to rapidly increase6. In acute 
myocardial infarction, increased pro-ENK was associated with renal dysfunction and predicted major cardiac 
events7. These results suggest a potential of pro-ENK as a novel cardiorenal biomarker, although its role in chronic 
and acute heart failure has not been established. Here, we evaluate the association between pro-ENK and indices 
of glomerular and tubular function and clinical outcome in patients with acute and chronic heart failure. 
 
Methods 
This study was performed in two populations. First, a cardiorenal mechanistic cohort was used to investigate the 
association between pro-ENK and renal function including hemodynamic parameters which were measured by 
radioactive tracers in stable chronic heart failure patients8, 9. Second, the PROTECT (Placebo-controlled Randomized 
study of the selective A1 adenosine receptor antagonist rolofylline for the patients hospitalized with acute heart 
failure and volume Overload to assess Treatment Effect on Congestion and renal functTion) study cohort (acute 
heart failure cohort) was used to study the association between pro-ENK and prognosis in patients with acute heart 
failure10. Measurement of pro-ENK was performed using a sandwich immunoassay with antibodies against the 
proenkephalin A 119-159 peptide by Sphingotec inc.5, 7. The lower detection limit was 5.5 pmol/L. Intra- and inter-
assay coefficients of variation were 6.4 and 9.5% at 50 pmol/L, and 4.0 and 6.5% at 150 pmol/L, respectively. The 
normal value of pro-ENK was measured in a general population, and determined as 46.6 ±14.1 pmol/L and 
median value of 45 (range: 9-518) pmol/L11. The 99th percentile upper reference limit of pro-ENK in healthy subjects 
was 80 pmol/L11.  
 
Renal mechanistic cohort (chronic heart failure) 
Patient selection and measurement procedure of renal hemodynamic parameters have been described elsewhere8, 
9. In brief, 120 ambulatory heart failure patients with left ventricular ejection fraction (LVEF) <45% on stable doses 
of ACE inhibitor or ARB for at least one month were included at University Medical Centre Groningen. All patients 
who consented to participate underwent GFR and effective renal plasma flow measurement using 125I-Iothalamate 
and 131I-Hippuran. Renal blood flow (RBF) was calculated as effective renal plasma flow/1-haematocrit. GFR and 
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RBF were expressed per body surface area. pro-ENK values were measured in 95 available plasma samples. Serum 
cystatin C levels were measured by nephelometry. Urinary tubular markers including neutrophil gelatinase-
associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminide for N-acetyl-β-D-glucosaminidase (NAG), and Kidney 
Injury Molecule 1 (KIM-1) were also determined by ELISA as previously described9.  
 
Acute heart failure cohort  
We also measured pro-ENK in the PROTECT study cohort. The details of the design, results, and conclusions of this 
study have already been published10, 12, 13. In brief, 2,033 acute heart failure patients with renal function impairment 
(estimated creatinine clearance between 20 to 80 mL/min with Cockcroft–Gault formula) were included and 
randomized to rolofylline or placebo. The protocol of the PROTECT study was approved by the ethics committee at 
each participating center, and written informed consent was obtained from all participants. We measured pro-ENK 
in 1,589 patients at baseline (day 1) 1,465 patients at day 2, and 1,200 patients at day 7 as samples were available. 
The following biomarkers were also evaluated at baseline; albumin, blood urea nitrogen (BUN), creatinine, glucose, 
hemoglobin, potassium, sodium, total cholesterol, triglycerides, uric acid and white blood cell count were 
measured by ICON Laboratories, Farmingdale, New York. N-Terminal pro Brain Natriuretic Peptide (NT-proBNP) was 
determined by screening using commercial assays available at study sites. NGAL and C-reactive protein were 
measured in available frozen plasma samples by Alere Inc., San Diego, CA, USA. NGAL was measured using sandwich 
enzyme-linked immunosorbent assays (ELISA) on a microtiter plate; C-reactive protein was measured using a 
competitive ELISA on a Luminex platform.  
We also evaluated the association between worsening renal function (WRF), pre-defined in PROTECT as a creatinine 
increase of ≥0.3 mg/dL from baseline (day 1) value or initiation of hemofiltration or dialysis at any time between 
day 1 to day 4.   
The prognostic value of pro-ENK was evaluated with 1,589 AHF patients with available Pro-ENK value at baseline 
using three endpoints: all-cause mortality within 180 days, heart failure rehospitalization through 60 days, and 
death or cardiovascular or renal rehospitalization through day 60 days14.  
 
Statistical analysis 
In both cohorts, data are expressed as mean and standard deviation for normally distributed variables, and as 
median with interquartile range for non-normally distributed data. Categorical data are expressed as numbers and 
percentages. The relationship between baseline characteristics and tertiles of pro-ENK were compared by using 
one-way analysis of variance test, Kruskal-Wallis test, or chi-squared tests where appropriate. A post-hoc test for 
pairwise comparison was performed with Bonferrroni correction. When necessary, variables were transformed for 
further analyzes. Stepwise multiple linear regression analysis was performed using backward elimination with a P 
value <0.10 as the criterion for retention after including all variables with P value <0.10 in univariate analysis to 
identify factors independently associate to pro-ENK levels.  
In the acute heart failure cohort, univariate logistic regression was performed to evaluate predictability of pro-ENK 
for WRF. If pro-ENK was significant in univariate logistic regression, multivariable logistic regression was performed 
to adjust for baseline creatinine levels to evaluate additive predictability for WRF. The longitudinal trajectory of 
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pro-ENK over time (day 1, day 2 and day 7) was assessed by using linear mixed effect models to account for within-
individual correlation of repeatedly measured values of pro-ENK. For this analysis, we excluded patients who died 
within 7 days. Identification of subjects was included as random effects, and time was modeled linearly. We used 
age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, serum sodium, log blood urea 
nitrogen, log creatinine, and albumin as fixed effects as these were suggested as factors of prognostic predictive 
value in this cohort15. For prognostic analysis, we adjusted log pro-ENK by a model that was previously defined for 
this cohort, including age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, sodium, 
log blood urea nitrogen, log creatinine and albumin.15. In this cohort, predictability of this model was confirmed to 
be similar to more complex models for outcome of all-cause mortality within 180 days, death or rehospitalization 
for any reason within 30 days, and cardiovascular or renal rehospitalization within 30 days. We evaluated prognostic 
predict ability of pro-ENKN in three multivariable Cox models: adjusted for age and gender (Model 1), adjusted for 
age, gender, creatinine, and BUN (Model 2), and adjusted for the clinical model (Model 3). A two-tailed P value < 
0.05 was considered statistically significant. Statistical analyses were performed using R version 3.1.2 (R Foundation 
for Statistical Computing, Vienna, Austria). ISBN 3-900051-07-0, URL http://www.R-project.org.  
 
Results 
Renal mechanistic cohort 
Patient characteristics 
Baseline characteristics are shown in Table 1. The mean age was 60±12 years, 75 patients (79%) were male, and 
mean LVEF was 29±10%. The median value of pro-ENK was 62.2 (IQR: 48.5 –92.5) pmol/L (Figure1), and 28 (29.5%) 
patients had pro-ENK levels above 99th percentile upper reference limit of pro-ENK in healthy subjects. Higher pro-
ENK tertiles were associated with higher age, females, lower blood pressure, higher NYHA class, greater diuretics 




Figure 1. Baseline pro-ENK values in renal mechanistic cohort and acute heart failure cohort 
The box represent interquartile ranges, the horizontal line in each box represents the median, and the whiskers 
show the 10-90 percentile range. 
 
Correlation between renal markers and pro-ENK   
Supplemental Table 1 shows the result of univariate linear regression analysis between log pro-ENK, renal markers 
and renal hemodynamic parameters. pro-ENK values were strongly and significantly associated with creatinine, 
BUN, Urinary Albumin Excretion, Cystatin C, GFR, and RBF but not with urinary tubular markers (NAG, NGAL, and 
KIM-1).  
 
Table 2 shows the result of multivariable linear regression analysis for pro-ENK. In the final model (R2=0.616), higher 
log pro-ENK levels were associated with lower GFR (standardized beta = -0.377) higher BUN, higher NT-proBNP, 















(n=32) P value 
pro-ENK (median, [min-max], pmol/mL) 62.2 [29.3-306.6]   45.7 [29.3-53.2] 62.2 [53.5-75.5] 102.5 [76.1-306.6] 
Age (yrs) 60±12   56±11†  61±11  63±12 0.034 
Male (%) 75 (79)    27 (84)  28 (90)‡  20 (63)  0.017 
Body surface area (m2) 2.0±0.2   2.1±0.2† 2.0±0.2 1.9±0.2 0.003 
Systolic blood pressure (mmHg) 120±21  130 ±20† 121 ±19‡ 109 ±20 <0.001 
Diastolic blood pressure (mmHg)  69±12    75 ±10†  72 ±11‡  61 ±11 <0.001 
Heart rate (bpm)  65±13   64 ±11  65 ±15  67 ±12 0.815 
Ischemic etiology (%) 52 (55)   15 (47)  20 (65)  17 (53)  0.363 
Diabetes (%) 13 (14)   6 (19)   2 (7)   5 (16)  0.338 
Smoking current or Ex (%) 47 (49)   13 (43) 19 (63) 15 (52) 0.297 
NYHA III or IV (%) 34 (36)   4 (13)†  11 (36)  19 (59)  <0.001 
LVEF (%)  29±10    30±9†  28±10  27±10 0.441 
Medication       
ACE-I (%) 78 (82)   27 (84)  27 (87)  24 (75)  0.419 
ARB (%) 18 (19)   5 (16)   5 (16)   8 (25)  0.562 
Beta blocker (%) 80 (84)   27 (84)  26 (84)  27 (84)  0.998 
Mineralocorticoid Receptor Antagonist 
(%) 
28 (30)   8 (25)   5 (16)‡  15 (47)  0.022 
Diuretics (%) 63 (66)  18 (56) 18 (58) 27 (84) 0.029 
Hemoglobin (g/dL)  14.0±1.4     14.3±1.1†   14.0±1.0‡   13.2±1.6 0.001 
Hematocrit (%)  42±4    42±3†   43±3‡   39±5 0.001 
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Renal function       
Creatinine (mg/dL) 1.2 (1.0-1.4)    1.0 (1.0-1.2)† 1.1 (1.1-1.3)‡ 1.5 (1.2-1.8) <0.001 
BUN (mg/dL)  20.4 (16.7-29.1)  16.7 (14.2-19.2)*† 19.9 (18.4-22.4)‡ 33.2 (24.7-41.5) <0.001 
Cystatin C (mg/L) 0.82 (0.70-1.02)   0.69 (0.49-1.78)*† 0.81 (0.59-1.12)‡ 1.19 (0.64-2.09) <0.001 
GFR (mL/min/1.73m2) 72.4±27.9   92.2±23.4*†  77.2±15.2‡  47.2±22.5 <0.001 
RBF (mL/min/1.73m2) 450.1±162.2   563.3±145.2*† 470.7±94.4‡ 307.5±138.4 <0.001 
FF (%) 28.0 (25.0-29.9)   28.4 (25.8-30.1)  28.3 (26.6-29.2)   26.5 (20.4-29.6) 0.122 
Urinary KIM-1 (ng/gCr) 
354.6   386.9 276.5 305.2 
0.909 
(218.4-604.7)   (219.7-536.7) (207.5-630.1) (220.3-549.2) 
Urinary NAG (U/gCr) 12.9 (6.5-16.9)    13.3 (6.0-17.2)   10.3 (6.5-12.8)‡   15.0 (13.1-19.6) 0.035 
Urinary NGAL (μg/gCr) 177.6 (61.1-341.8)   152.8 (52.7-314.0) 187.7 (79.9-329.4) 
  153.2 (57.5-
366.5) 
0.563 
Urinary Creatinine (mmol/L)  6.2 (4.6-8.4)    7.4 (5.1-9.4)   6.3 (4.6-8.0)    6.1 (4.6-7.7) 0.391 
Urinary Albumin (mg/L)  5.4 (3.3-11.8)     4.8 (2.2-8.9)†   4.8 (3.2-7.0)‡   15.0 (4.6-41.0) 0.003 
† P < 0.05, Tertile 1 vs Tertile 2 
‡ P < 0.05, Tertile 1 vs Tertile 3 
§ P < 0.05, Tertile 2 vs Tertile 3  
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BUN, blood urea nitrogen; GFR, glomerular filtration rate; KIM-1, kidney injury molecule 1; 
LVEF, left ventricular ejection fraction; NAG, N-acetyl-ϐ-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain natriuretic peptide; 




Table 2. Multivariable linear regression for pro-ENK in renal mechanistic and acute heart failure cohort 
Multivariate linear regression for Log PENK 
Variables Standardized Beta t  P value 
Renal mechanistic cohort (Adjusted R2=0.616) 
GFR per BSA -0.377 -3.189 0.002 
Log BUN 0.321 2.996 0.004 
Log NT-proBNP 0.284 3.092 0.003 
NYHA III or IV -0.245 -2.617 0.010  
Systolic blood pressure -0.197 -2.845 0.005 
Acute heart failure cohort (Adjusted R2=0.469) 
Creatinine 0.445 14.30  <0.001 
Male -0.21 -9.647 <0.001 
Age 0.163 7.583 <0.001 
BNP 0.147 6.899 <0.001 
BUN 0.119 3.819 <0.001 
Hemoglobin -0.113 -5.273 <0.001 
BMI -0.097 -4.507 <0.001 
Glucose  -0.085 -4.167 <0.001 
Potassium 0.077 3.687 0.002 
Uric acid 0.056 2.442 0.015 
BMI, body mass index; BNP; brain natriuretic peptide; BUN, blood urea nitrogen; GFR, glomerular filtration rate; 
NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; pro-ENK, proenkephalin 
 
 
Acute heart failure cohort 
Patient characteristics  
Baseline characteristics of the PROTECT AHF cohort according to pro-ENK tertiles are shown in Table 3. The mean 
age was 71±11 years, 1049 (66%) were male, and mean LVEF was 33±13%. The median value of pro-ENK was 
104.9 (IQR: 73.7 – 146.6) pmol/L (Figure 1), and 1092 (68.7%) patients had pro-ENK levels above 99th percentile 
upper reference limit of pro-ENK in healthy subjects. At baseline, higher pro-ENK levels were associated with higher 
age, females, lower diastolic blood pressure, preserved LVEF (≥45%), history of diabetes, higher creatinine, higher 










Tertile 1 Tertile 2 Tertile 3 
P value (n=530) (n=529) (n=530) 
pro-ENK (median, [min-max]) 104.9 [6.5-511.7]  64.4 [6.5-82.9] 104.9 [83.0-131.8] 173.5 [131.9-511.7] 
Age (years) 71±11  67±11†‡ 71±11§ 74±10 <0.001 
Male (%) 1049 (66)  379 (72)‡ 343 (65) 327 (62) 0.003 
Systolic blood pressure 
(mmHg) 
125±17  126±17 123±18 125±18 0.067 
Diastolic blood pressure 
(mmHg) 
74±12  76±11†‡ 73±12 72±12 <0.001 
Pulse rate (bpm) 80±16  82±15† 80±15 78±16 0.001 
Assigned to Rolofylline (%) 1065 (67)  352 (66) 354 (67) 359 (68) 0.899 
LVEF (%) 32±13  31±13‡ 31±13§ 35±13 0.002 
HFpEF (LVEF ≥45%) (%)* 152 (20)  35 (15)‡ 49 (19) 68 (26) 0.011 
Prior medication (%)        
ACE-I  993 (63)  352 (66)‡ 333 (63) 308 (58) 0.019 
ARB  241 (15)  60 (11)†‡ 91 (17) 90 (17) 0.01 
Beta blocker  1196 (75)  394 (74) 404 (77) 398 (75) 0.707 
Calcium channel blocker  225 (14)  59 (11)‡ 69 (13) 97 (18) 0.002 
Aldosterone inhibitor  718 (45)  263 (50)‡ 240 (46) 215 (41) 0.012 
Digoxin  457 (29)  177 (33)‡ 171 (32)§ 109 (21) <0.001 
Past history (%)       
Hypertension  1272 (80)  414 (78) 419 (79) 439 (83) 0.132 
Diabetes  733 (46)  234 (44) 233 (44) 266 (50) 0.072 
14 
 
Smoking  310 (20)  118 (22) 103 (20) 89 (17) 0.079 
Heart failure hospitalization  782 (49)  234 (44)† 280 (53) 268 (51) 0.013 
Atrial fibrillation  860 (54)  266 (51) 303 (57) 291 (55) 0.078 
Worsening renal function (%)  371 (23)  99 (19)‡ 115 (22)§ 157 (30) <0.001 
Biomarkers        
WBC count (x109/L) 7.42 (6.04-9.22)  7.43 (6.25-9.05) 7.40 (6.13-9.15) 7.42 (5.84-9.40) 0.929 
Hemoglobin (g/dL) 12.5 (11.2-13.8)  13.1 (11.9-14.4)†‡ 12.7 (11.4-13.8)§ 11.7 (10.6-12.9) <0.001 
Total cholesterol (mg/dL) 141 (117-173)  149 (123-178)†‡ 139 (116-168) 136 (114-167) 0.001 
Triglycerides (mgl/dL) 88 (65-122)  95 (72-126)†‡ 82 (61-120) 84 (63-120) <0.001 
Albumin (mgl/dL) 3.8 (3.6-4.1)  3.9 (3.6-4.2)‡ 3.9 (3.6-4.1)§ 3.8 (3.5-4.1) <0.001 
BUN (mg/dL) 30 (22-41)  22 (18-28)†‡ 29 (23-38)§ 42 (32-56) <0.001 
Creatinine (mg/dL) 1.4 (1.1-1.8)  1.1 (0.9-1.3)†‡ 1.4 (1.2-1.6)§ 1.8 (1.5-2.3) <0.001 
NGAL (ng/mL) 82.4 (52.8-135.1)  56.6 (39.8-82.9)†‡ 75.8 (53.9-112.5)§ 132.8 (87.8-198.8) <0.001 
Sodium (mEq/L) 140 (137-142)  140 (137-143)‡ 140 (137-142) 139 (137-142) 0.013 
Potassium (mEq/L) 4.2 (3.9-4.6)  4.1 (3.8-4.5)‡ 4.2 (3.8-4.6)§ 4.3 (3.9-4.8) <0.001 
Glucose (mg/dL) 128 (103-164)  133 (106-175)†‡ 124 (101-162) 126 (101-160) 0.008 
Uric acid (mg/dL) 8.8 (7.2-10.6)  7.9 (6.6-9.5)†‡ 8.9 (7.3-10.6)§ 9.6 (7.9-11.6) <0.001 
BNP (pg/mL) 
449.2  319.3†‡ 510.9 542 
<0.001 
 (255.9-801.5)   (201.6-556.6)  (277.8-854.9)  (293.9-968.9) 





14707 (8037-29315) 0.303 
* P < 0.05, Tertile 1 vs Tertile 2 
† P < 0.05, Tertile 1 vs Tertile 3 
‡ P < 0.05, Tertile 2 vs Tertile 3  
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; HFpEF, heart 
failure with preserved ejection fraction; LVEF, left ventricular ejection fraction; NGAL, Neutrophil Gelatinase-Associated Lipocalin; pro-ENK , proenkephalin; WBC, white blood cell 
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*LVEF data was only available in 763 (48.0%) patients. 
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Correlation between covariates and pro-ENK 
The result of univariate and multivariable linear regression analysis of pro-ENK is shown in Supplemental Table 2 
and Table 2, respectively. Serum creatinine was the primary determinant of log pro-ENK among baseline variables 
(standardized beta = 0.422, P<0.001), and followed by females, higher age, higher BNP, and higher BUN in PROTECT 
acute heart failure cohort.  
 
Association between pro-ENK and WRF 
High pro-ENK values at baseline were associated with a higher incidence of worsening renal function. In univariate 
logistic regression, log pro-ENK was significantly associated with worsening renal function (Odds ratio: 1.47, 95% 
CI: 1.18-1.84, P<0.001). However, the significance was attenuated after adjustment for log creatinine (Odds ratio: 
1.24, 95% CI: 0.95-1.61, P=0.119). In a sensitivity analysis, log pro-ENK was not a significant predictor of WRF with 
other definitions (≥25% increase or ≥25% and ≥0.3 mg/dL increase in creatinine from baseline levels) even in a 
univariate logistic regression analysis (data not shown). 
 
Association of pro-ENK with prognosis 
Kaplan-Meier curves of each tertile for mortality through day 180 are shown in Figure 2. Higher tertiles of pro-ENK 
were associated with 180 days mortality (P<0.001). In Cox regression models, high log pro-ENK levels were 
significantly associated with all of the three outcomes; death through 180 days, heart failure rehospitalization 
through day 60, and death or cardiovascular or renal rehospitalization through day 60 in univariable Cox regression 
analysis, and even after adjustment for age and gender (Model 1). Log pro-ENK was a significant predictor only for 
endpoint of death through day 180 even after being adjusted by age, gender, creatinine, and BUN (Model 2). 
However, log pro-ENK lost its significance for all of outcomes after adjustment for the PROTECT prognostic model; 
including age, history of heart failure hospitalization, severity of peripheral edema, systolic blood pressure, serum 
sodium, BUN, creatinine, and Albumin (Model 3) (Table 4). There was no significant interaction between rolofylline 
treatment and prognostic predictive ability of pro-ENK for any of outcomes (all P for interaction >0.3).  
 
Figure 2. Kaplan-Meier curves of each tertile of pro-ENK in acute heart failure cohort 
Survival curves of each pro-ENK tertile in acute heart failure cohort. 
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Model 1 (adjusted by age 
and gender)   
  
Model 2 (adjusted by Model 1 + 
log Creatinine and log BUN)   
  
Model 3 (adjusted by 
clinical model*) 
HR  95%CI P value HR  95%CI P value HR  95%CI P value HR  95%CI P value 




227 (14.3) 1.43 1.12-1.84 0.005  1.53 1.18-1.97 0.001  1.01 0.72-1.38 0.933  1.01 0.74-1.36 0.977 
Death or Cardiovascular or 
Renal Rehospitalization 
through Day 60  
457 (28.8) 1.58 1.33-1.89 <0.001   1.63 1.36-1.96 <0.001   1.18 0.94-1.50 0.162   1.15 0.91-1.45 0.257 
BUN, blood urea nitrogen 




Serial changes in pro-ENK over time and prognosis 
We compared the trajectory of pro-ENK values at day 1, day 2, and day 7 and percent change from baseline to day 
2 and day 7 between patients with and without death through 180 days after excluding 29 patients who died within 
7 days of admission (Figure 3). Baseline pro-ENK value was higher in patients who died compared with those who 
were alive. In the mixed effect model, there was no significant difference between patients who died or survived 
with regard to absolute or relative changes over time (P=0.760 and P=0.258, respectively). Similar results were 
obtained for the endpoints of heart failure rehospitalization through 60 days and death or cardiovascular or renal 
rehospitalization through day 60 (P>0.05 for all) (Supplemental Figure 1). We also evaluated the prognostic 
importance of percent change in pro-ENK from baseline (day 1) to day 2 and from baseline to day 7 as a numeric 
variable, and neither showed independent prognostic information in multivariate Cox regression analysis 
(Supplemental Table 3). 
 
 
Figure 3. Changes in pro-ENK in patients with and without death through 180 days 
Median value is expressed as open circle and interquartile range is expressed as error bars. 
 
Discussion 
In acute and chronic heart failure, pro-ENK levels were higher in acute HF compared with chronic HF. Pro-ENK was 
clearly associated with renal blood flow and glomerular filtration rate but not with tubular function. In acute heart 
failure patients, pro-ENK was associated with clinical outcome, but after adjustments for established prognostic 
predictors including preexisting renal markers, this association was lost. Therefore, pro-ENK seems to be a renal 
marker, but does not seem to have additive value on top of the established prognostic markers.   
 
Pro-ENK as a renal biomarker in heart failure patients 
The endogenous opioid system is one of the most studied innate pain-relieving systems. In addition, the 
endogenous opioid system has also been suggested to have a negative effect on the cardiovascular system. Two 
observational studies suggested that activity of the endogenous opioid system was activated in heart failure 
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patients compared with healthy subjects16, 17. Additionally, in an experimental dog model of congestive heart 
failure, delta-opioid receptor (OPR) was specified as a more relevant receptor subtype among several OPRs in terms 
of hemodynamic regulation18. In this study, a selective antagonist for delta-OPR increased aortic pressure, cardiac 
output, and blood flow to the myocardium and kidney. These results suggested that delta-OPR plays a main role in 
the opioid system as a cardiovascular modulator, and measuring activity of enkephalin - a specific peptide to delta-
OPR - might be useful to evaluate the effect of the opioid system in heart failure patients. Recently, pro-ENK was 
suggested as a stable and reliable surrogate marker of enkephalin and it became possible to evaluate enkephalin 
activity in vivo5.   
In the present study, we showed that levels of pro-ENK were relatively high in both acute and chronic heart failure 
patients when pro-ENK value derived from normal subject was used as reference. Furthermore, both in the chronic 
and acute heart failure cohorts we found a consistent association between pro-ENK and several renal markers. 
Moreover, precise evaluation of renal function in the chronic heart failure cohort showed that pro-ENK levels were 
strongly associated with renal blood flow and glomerular filtration rate. These results are in agreement with the 
finding that delta-OPR was highly expressed in the kidney and inhibition of delta-OPR increased kidney blood flow 
in an experimental heart failure model4, 18. Moreover, pro-ENK was positively correlated with albuminuria in the 
chronic heart failure cohort. These findings show that pro-ENK is a novel renal marker. The pathophysiologic 
mechanism or rather determinants of pro-ENK including renal clearance has to be evaluated in future studies.   
We evaluated the association between pro-ENK and worsening renal function in acute heart failure, and found that 
pro-ENK was not a predictor of worsening renal function in heart failure patients independent from serum 
creatinine. This is in line with a previous study that evaluated the association between pro-ENK values before 
surgery and acute kidney injury in patients undergoing cardiac surgery. In this study, baseline pro-ENK values were 
strongly associated with baseline creatinine. Pro-ENK levels were also associated with acute kidney injury after 
surgery, but did not outweigh creatinine6. These and our results showed that the association between pro-ENK and 
worsening renal function can be attributed to the significant association with creatinine, and pro-ENK by itself 
provides limited additive information to creatinine in terms of changes in renal function.  
 
Prognostic information of pro-ENK in heart failure 
In our present analysis, pro-ENK was not an independent predictor of prognosis in acute heart failure cohort in 
spite of its association with renal function and severity of heart failure. This result suggests that pro-ENK provides 
limited additional prognostic information to preexisting prognostic markers of heart failure patients including renal 
biomarkers.  
Our findings are inconsistent with previous two studies which investigated prognostic role of pro-ENK in patients 
with myocardial infarction and non-symptomatic heart failure patients, where higher pro-ENK levels were an 
independent predictor of a combined endpoint of death and adverse events even after adjustment for other 
prognostic factors7, 19. This discordance might be due to a difference in study population. Another possible 
explanation is an association between pro-ENK and BUN. In the aforementioned study of myocardial infarction 
patients, pro-ENK was an independent predictor of mortality after being adjustment for the Global Registry of 
Acute Coronary Events (GRACE) model20, and pro-ENK showed incremental prognostic information. However, the 
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GRACE model does not include information about BUN, and as a consequence, it is unclear whether pro-ENK would 
have been a significant predictor of events if the model would have been adjusted for BUN. Recent studies showed 
that BUN was an independent predictor of mortality also in acute myocardial infarction patients even after being 
adjusted by eGFR21, 22 and indeed pro-ENK was significantly and strongly correlated with BUN in our cohort. Recently, 
Arbit et al. investigated the role of pro-ENK in patients referred to echocardiography and categorized into stage A 
or B HF (symptomatic HF patients were excluded). Pro-ENK correlated with serum creatinine and eGFR, and was an 
independent predictor of worse prognosis after adjustment for some prognostic factors. However, in contrast to 
the present study, these patients were asymptomatic and were not adjusted for BUN, which was a strong 
confounder in our study19. The relationship between pro-ENK and BUN might be an explanation why pro-ENK was 
an independent prognostic predictor in these previous studies but not in our cohort.  
 
Limitations 
This study has important limitations due to its retrospective character. In the chronic HF cohort, number of patients 
were limited so that prognostic predictability of pro-ENK in a chronic heart failure population remains to be 
elucidated. In the acute heart failure cohort, only heart failure patients with mild renal impairment were included 
by study design. Echocardiographic measurements were obtained in only less than half of all patients. Moreover, 
pro-ENK levels were not available in some patient of both cohorts due to availability of plasma, which could have 
influenced the results despite the fact that there was no significant difference in event rate for any endpoints 
between patients with available samples and those without (all P value >0.5).   
 
Conclusion   
Pro-ENK levels were higher in acute heart failure when it compared with chronic heart failure. Pro-ENK levels were 
strongly associated with glomerular function and renal blood flow, but not with tubular damage. Pro-ENK has 
limited additive prognostic predictive information on top of existing renal markers in this cohort of acute heart 
failure.  
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Supplemental Table 1. Univariate linear regression for pro-ENK in renal mechanistic cohort 
Variables Standardized Beta t P value 
Age  0.29 2.922 0.004 
Male  -0.257 -2.566 0.012 
BSA -0.362 -3.727 <0.001 
Systolic blood pressure -0.375 -3.897 <0.001 
Diastolic blood pressure   -0.475 -5.201 <0.001 
Heart rate  0.008 0.081 0.936 
Ischemic etiology  0.012 0.115 0.909 
Diabetes  -0.029 -0.279 0.781 
Smoking current or Ex 0.048 0.449 0.655 
NYHA III or IV  0.417 4.421 <0.001 
LVEF  -0.134 -1.301 0.197 
Medication    
ACE-I -0.119 -1.158 0.25 
ARB 0.109 1.062 0.291 
Beta  blocker  -0.025 -0.246 0.806 
Aldosterone antagonist 0.326 3.321 0.001 
Diuretics 0.27 2.701 0.008 
Hemoglobin  -0.34 -3.452 <0.001 
Hematocrit  -0.326 -3.213 0.002 
Log NT-ProBNP 0.588 7.006 <0.001 
Renal function    
Creatinine  0.606 7.349 <0.001 
Log BUN   0.714 9.794 <0.001 
Cystatin C 0.706 8.628 <0.001 
GFR -0.707 -9.590 <0.001 
RBF -0.66 -7.300 <0.001 
FF -0.328 -3.353 0.002 
Urinary KIM-1 -0.061 -0.500 0.619 
Urinary NAG  0.17 1.421 0.16 
Urinary NGAL 0.197 1.654 0.103 








Supplemental Table 2. Univariate linear regression for pro-ENK in acute heart failure cohort 
Variables Standardized Beta t P value 
Age 0.248 10.19 <0.001 
Male gender  -0.095 -3.814 <0.001 
Systolic blood pressure -0.016 -0.633 0.527 
Diastolic blood pressure -0.091 -3.629 <0.001 
Pulse rate (bpm) -0.065 -2.609 0.009 
LVEF  0.109 3.021 0.003 
Prior medication    
ACE-I -0.063 -2.533 0.011 
ARB  0.039 1.558 0.119 
Beta blocker  -0.001 -0.039 0.969 
Calcium channel blocker 0.097 3.898 <0.001 
Aldosterone inhibitor  -0.063 -2.53 0.012 
Digoxin -0.088 -3.542 <0.001 
Past history       
Hypertension 0.051 2.035 0.042 
Diabetes 0.056 2.244 0.025 
Smoking  -0.075 -2.812 0.005 
Heart failure hospitalization 0.064 2.553 0.011 
Atrial fibrillation  0.049 1.942 0.052 
Biomarkers at baseline       
WBC 0.007 0.275 0.783 
Hemoglobin -0.269 -10.48 <0.001 
T-Cholesterol -0.001 -2.528 0.012 
Triglycerides -0.041 -1.598 0.11 
Albumin -0.156 -4.819 <0.001 
BUN 0.517 23.87 <0.001 
Creatinine 0.552 26.09 <0.001 
Plasma NGAL 0.299 12.41 <0.001 
Sodium -0.06 -2.374 0.018 
Potassium 0.163 6.358 <0.001 
Glucose -0.075 -2.924 0.004 
Uric acid 0.232 9.228 <0.001 
BNP 0.245 10.05 <0.001 






Supplemental Table 3. Univariable and multivariable Cox regression of percent change in pro-ENK value from baseline to day2 and day7 for outcomes (per 10% increase) 
  
Outcomes 
Percent relative changes from Day 1 to Day 2   
  
  
Percent relative changes from Day 1 to Day 7 
Univariable Cox 
 
Multivariate Cox Univariable Cox 
 
Multivariate Cox 
HR 95%CI P value HR 95%CI P value HR 95%CI P value HR 95%CI P value 
Death through Day 180 1.01 0.99-1.02 0.353      1.00 0.99-1.01 0.638     
HF Rehospitalization through Day 
60 
1.01 1.00-1.02 0.030  1.01 1.00-1.02 0.157   1.01 1.00-1.02 0.044  1.01 0.99-1.02 0.279 
Death or Cardiovascular or Renal 
hospitalization through Day 60 



















Supplemental Figure 1. Changes in pro-ENK in patients with and without (A) heart failure rehospitalizaiton through day 60 and (B) death or cardiovascular or renal 
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The blood urea nitrogen (BUN)/Creatinine ratio has been proposed as a useful parameter in acute heart failure 
(AHF), but data on the normal range and the added value of the ratio compared to its separate components in 
patients with AHF are lacking. The aim of this study is to define the normal range of BUN/Creatinine ratio and to 
investigate its clinical significance in patients with AHF. 
 
Methods  
In 4484 subjects from the general population without cardiovascular comorbidities, we calculated age and sex 
specific normal values of the BUN/Creatinine ratio, deriving a higher and lower than normal range of 
BUN/Creatinine ratio (exceeding the 95% prediction intervals). Association of abnormal range to prognosis was 
tested in 2033 AHF patients for the outcome of all-cause death through 180 days, death or cardiovascular or renal 
rehospitalization through 60 days, and heart failure rehospitalization within 60 days.   
 
Results  
In a cohort of AHF patients, 482 (24.6%) and 28 (1.4%) HF patients were classified into higher and lower than 
normal range groups, respectively. In Cox regression analysis, higher than normal range of BUN/Creatinine ratio 
group was an independent predictor for all-cause death (HR: 1.86, 95% CI: 1.29-2.66) and death or cardiovascular 
or renal rehospitalization (HR: 1.37, 95% CI: 1.03-1.82), but not for heart failure rehospitalizaiton (HR: 1.23, 95% CI: 
0.81-1.86) after adjustment for other prognostic factors including both creatinine and BUN.  
 
Conclusions 
In AHF patients, BUN/Creatinine higher than age and sex specific normal range is associated with worse prognosis 
independently from both creatinine and BUN. 
 





Renal dysfunction is one of the most common comorbidities in acute heart failure (HF) and it is related to poor 
prognosis1. Creatinine and blood urea nitrogen (BUN) are nitrogenous end products of protein metabolism, and 
freely filtered at the glomerulus because both are relatively small molecules. Therefore, both serum creatinine and 
BUN are well recognized as renal markers and have been shown to be associated with outcome in these patients1, 
2. However, there is a difference in tubular handling between these two renal markers: while creatinine is but not 
reabsorbed, approximately 40 to 50% of BUN is reabsorbed in the tubules. As this reabsorption process is directly 
or indirectly regulated by neurohormonal activity3, the BUN to Creatinine (BUN/Creatinine) ratio has been 
proposed as a metric of neurohormonal activity which may have prognostic value in HF4-10. However, normal values 
of BUN/Creatinine ratio are unknown and therefore qualitative evaluation and use of BUN/Creatinine has been 
limited by a lack of reference values. To better understand the distribution, etiology, and prognostic implication of 
BUN/Creatinine ratio, we set out to establish normal values of BUN/Creatinine ratio in the general population. 
Subsequently, we applied these values to a cohort of acute HF patients.            
 
Methods 
The Prevention of Renal and Vascular End-stage Disease (PREVEND) study cohort was used to investigate 
BUN/Creatinine ratio in general population. From these normal values, we derived a normal range, which was 
applied on a cohort of 2033 patients from the Placebo-controlled Randomized study of the selective A1 adenosine 
receptor antagonist rolofylline for the patients hospitalized with AHF and volume Overload to assess Treatment 
Effect on Congestion and renal functTion (PROTECT) study cohort.   
 
PREVEND cohort (general population) 
The PREVEND study was designed to prospectively investigate the natural course of increased levels of urinary 
albumin excretion and its relation to renal and CV disease in a large cohort drawn from the general population. 
Details of this protocol and results have been described elsewhere11, 12. In brief, all inhabitants of the city of 
Groningen, The Netherlands, aged 28 to 75 years (N=85,421) were asked to send in a first morning urine sample 
and complete a short questionnaire on demographics and cardiovascular disease history. Of these subjects, 40,856 
responded (47.8%). After exclusion with insulin dependent diabetes mellitus and pregnant women, 6,000 subjects 
with urinary albumin excretion ≥10mg/L in their morning urine and randomly selected 2,592 subjects with urinary 
albumin excretion <10mg/L were further investigated in an outpatient clinic. These 8,592 subjects constitute the 
PREVEND cohort. BUN/Creatinine ratio was obtained in 7976 (92.8%) patients. In order to investigate 
BUN/Creatinine ratio in a cohort from the general population without cardiovascular comorbidities, we excluded 
3492 subjects from this cohort with a history of hypertension, hypercholesterolemia, diabetes or myocardial 
infarction.  
Excluded subjects were older, often male, and more often had a history of smoking compared to included subjects. 
All of the biomarkers, including creatinine and BUN, were higher in excluded subjects, and there was a small but 
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significant difference in BUN/Creatinine ratio between the included and excluded subjects (Supplemental Table 1). 
The remaining 4484 subjects were used for the present analysis.  
Creatinine was determined by Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, NY), an automated 
enzymatic method. BUN was measured from samples that were kept stored frozen at -80 degrees Centigrade from 
+/- 1997 until 2012. The BUN measurements were performed on a Roche Modular with UV kinetic assay, which is 
based on Talke and Schubert’s method and has been optimized for analyzers that permit kinetic measurements. 
All subjects gave written informed consent. The PREVEND study was approved by the local medical Ethical 
Committee and conducted in accordance with the Declaration of Helsinki.  
 
   
PROTECT cohort (acute heart failure patients) 
We evaluated the prognostic significance of BUN/Creatinine ratio in the PROTECT study cohort. Study design, 
primary results, and conclusions have been already published13-15. In brief, 2,033 patients with acute HF and renal 
function impairment (estimated creatinine clearance between 20 to 80 mL/min) were included and randomized to 
rolofylline or placebo. The protocol of the PROTECT study was approved by the ethics committee at each 
participating center, and written informed consent was obtained from all participants. BUN/Creatinine ratio was 
obtained in 1956 (96.2%) patients at baseline, and we divided the cohort into three groups according to 
upper/lower limits of 95% prediction intervals of BUN/Creatinine ratio calculated from the equation derived from 
the PREVEND cohort. An estimate of the glomerular filtration rate was calculated using the simplified Modification 
of Diet in Renal Disease (sMDRD) formula. Both serum BUN and creatinine were measured in a central laboratory 
(ICON Laboratories, NY). Creatinine was measured using substrate-triggered rate-blanked method.  
Worsening renal function (WRF) was defined as a creatinine increase of ≥0.3 mg/dL from baseline (day 1) value or 
initiation of hemofiltration or dialysis at any time between day 1 to day 4. The prognostic implication of lower and 
higher than normal range of BUN/Creatinine ratio was evaluated using three endpoints: all-cause mortality within 
180 days, death or cardiovascular or renal rehospitalization through day 60 days, and HF rehospitalization through 
60 days16.  
 
Statistical analysis 
Data are expressed as mean and standard deviation for normally distributed variables, and as median with 
interquartile range for non-normally distributed data. Categorical data are expressed as numbers and percentages.  
In the PREVEND study, patients with elevated urinary albumin excretion were overselected compared to those 
without. To overcome this limitation, a design-based analysis (statistical weighting method) was performed so that 
we can generalize our results to general population17.  
The relationship between baseline characteristics and each BUN/Creatinine group was compared by using one-way 
analysis of variance test, Kruskal-Wallis test, or chi-squared tests where appropriate. When necessary, variables 
were transformed for further analyses. Logistic regression was performed to evaluate the predictability of 
higher/lower than normal range of BUN/Creatinine ratio for WRF. For prognostic analysis, the hazard ratio of being 
higher/lower than normal range of BUN/Creatinine ratio group was adjusted by the clinical model previously 
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defined for this cohort in Cox regression model18. The prognostic predictability of this clinical model was confirmed 
to be similar to more complex models for the outcome of all-cause mortality within 180 days, death or 
rehospitalization for any reason within 30 days, and death or cardiovascular or renal rehospitalization within 30 
days in PROTECT cohort18. The proportional hazards assumption of Cox regression was tested by analysis of the 
scaled Schoenfeld residuals. For the variables did not meet this assumption, stratification was performed. For the 
outcome of heart failure rehospitalization through day 60, Fine and Gray competing risk proportional hazard 
regression model was used19. We also calculated continuous net reclassification improvement (NRI) and integrated 
discrimination improvement (IDI) with corresponding 95% confidence interval for combined logistic model of 
aforementioned clinical model and BUN/Creatinine ratio in relation to normal range (higher, within, and lower than 
normal range)20. A two-tailed P value < 0.05 was considered statistically significant. Statistical analysis were 




BUN/Creatinine ratio in general population 
The median BUN/Creatinine ratio in the 4484 subjects without cardiovascular comorbidities from the general 
population without cardiovascular risk factor was 15.0 (IQR: 12.9-17.6) (Figure 1). After evaluating linearity, we 
constructed a linear regression model for the association between age and log BUN/Creatinine ratio for males and 
females separately, because there was a significant interaction between sex and age on log BUN/Creatinine ratio 




Figure 1. Baseline BUN/Creatinine ratio in general population (PREVEND) and acute heart failure patients 
(PROTECT) 
 
Figure 2 shows the distribution of log BUN/Creatinine ratio in 4484 PREVEND subjects, and the regression line with 
95% prediction intervals by age for each sex. Log BUN/Creatinine varied widely and increased with age in both 
sexes. Log BUN/Creatinine ratio increased more with age in females compared to males.  
 
 
Figure 2. Scatter plot of association between age versus log BUN/Creatinine ratio by sex in general population 
(PREVEND) and acute heart failure patients (PROTECT)   
Solid lines express predicted log BUN/Creatinine ratio by age and sex with 95% prediction intervals (shaded area) 
for each sex. 
 
 
We additionally checked the association between age and creatinine and between age and BUN. Both creatinine 
and BUN increased with age both in males and females however, a significant interaction between age and sex was 
observed for BUN only (P for interaction=0.017) and not for creatinine (P for interaction=0.350) (Supplemental 
Figure 1).   
 
BUN/Creatinine ratio in acute heart failure cohort  
In the PROTECT study cohort, median BUN/Creatinine ratio was 21.1 (IQR: 17.5-26.2) which was significantly higher 
than in the control cohort without cardiovascular comorbidities (P<0.001) (Figure 1). The upper and lower 95% 
prediction limits were calculated from age and sex for each patient, and all patients were divided into three groups: 
higher than normal range of BUN/Creatinine ratio group (n=482; 24.7%), lower than normal range of 
BUN/Creatinine ratio group (n=28; 1.4%), and BUN/Creatinine ratio within normal range (n=1446; 73.9%). The 
baseline characteristics of each group are described in Table 1. At baseline, higher than normal range of 
BUN/Creatinine ratio was associated with lower age, higher BUN, higher NGAL, lower blood pressure, lower left 
ventricular ejection fraction, a HF hospitalization in the previous year, and lower plasma sodium level. There was 








Table 1. Baseline characteristics of each BUN/Creatinine ratio group in acute heart failure patients (PROTECT) 
Variables 
BUN/Creatinine ratio 





normal range  
(n=1446) 
BUN/Creatinine 




Age (years) 69±12 71±11 70±12 0.009 
Male gender (%) 342 (71) 948 (66) 17 (61) 0.073 
Systolic blood pressure 
(mmHg) 
118±17 126±17 134±19 <0.001 
Diastolic blood pressure 
(mmHg) 
71±12 75±12 79±10 <0.001 
Pulse rate (bpm) 79±15 81±16 81±14 0.046 
Assign to Rolofylline (%) 326 (68) 962 (67) 19 (68) 0.899 
LVEF* (%) 31±13 33±13 36±11 0.067 
HFpEF (LVEF ≥45%) (%) 41 (17) 134 (20) 5 (33) 0.282 
Prior medication (%)     
ACE-I  284 (59) 915 (63) 16 (57) 0.194 
ARB  96 (20) 205 (14) 3 (11) 0.008 
Beta blocker  380 (79) 1095 (76) 22 (79) 0.377 
Calcium channel blocker  45 (9) 214 (15) 4 (14) 0.009 
Aldosterone antagonist  256 (53) 602 (42) 7 (25) <0.001 
Digoxin  152 (32) 402 (28) 4 (14) 0.071 
Past history (%)     
Hypertension  348 (72) 1180 (82) 25 (89) <0.001 
Diabetes  236 (49) 644 (45) 10 (36) 0.141 
Smoking  105 (22) 289 (20) 7 (25) 0.588 
Heart failure 
hospitalization  
276 (57) 681 (47) 13 (46) 0.001 
Atrial fibrillation  274 (57) 772 (54) 12 (43) 0.196 
Worsening renal function 
(%) (≥0.3mg/dL from 
baseline) 
111 (23) 342 (24) 9 (32) 0.543 
BUN/Creatinine ratio 30.9 (27.8-35.6) 19.4 (16.7-22.5) 10 (9.9-11.2) <0.001 
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eGFR (mL/min/1.73m2) 46 (33-60) 46 (35-60) 48 (38-59) 0.898 
Biomarkers     
WBC count (x109/L) 7.26 (5.89-8.90) 7.50 (6.15-9.33) 7.56 (5.99-9.25) 0.167 
Hemoglobin (g/dL) 12.4±2.0 12.8±2.0 12.0±2.1 <0.001 
Total cholesterol (mg/dL) 26 (105-156) 147 (120-177) 159 (139-190) <0.001 
Triglycerides (mgl/dL) 82 (62-113) 90 (65-126) 106 (83-132) 0.003 
Albumin (mgl/dL) 3.8 (3.5-4.1) 3.9 (3.6-4.1) 3.8 (3.3-4.3) <0.001 
Blood urea nitrogen 
(mg/dL) 
45 (34-63) 27 (21, 35) 13 (11-15) <0.001 
Creatinine (mg/dL) 1.4 (1.1-1.9) 1.4 (1.1-1.7) 1.3 (1.1-1.6) 0.358 
Sodium (mEq/L) 139 (136-141) 140 (137-142) 141 (139-142) <0.001 
Potassium (mEq/L) 4.4±0.6 4.3±0.6 4.2±0.5 0.027 
Glucose (mg/dL) 128 (103-162) 126 (103-164) 113 (103-140) 0.534 
Uric acid (mg/dL) 9.9± 2.9 8.7±2.4 7.4±1.9 <0.001 
BNP (pg/mL) 529.4 (279.1-946.0) 
432.9 (248.1-
766.7) 









Plasma NGAL (ng/mL) 93.8 (57.2-151.1) 78.8 (52.2-128.4) 77.6 (55.7-124.2) 0.001 
 
We observed 462 cases of WRF, and there was no significant difference in the incidence of WRF between groups. 
Neither higher (odds ratio: 0.97, 95% CI: 0.76-1.23, P=0.780) nor lower (odds ratio: 1.53, 95% CI: 0.69-3.41, 
P=0.300) than normal range of BUN/Creatinine ratio were significantly associated with WRF in univariate logistic 
regression analysis. 
 
Kaplan-Meier curves of each group for mortality through day 180 are shown in Figure 3. Higher and lower than 
normal range of BUN/Creatinine ratio groups were associated with worse and better outcome compared to as 
predicted group, respectively (Log-rank: P<0.001). In univariate Cox regression models, higher than normal range 
of BUN/Creatinine ratio group was associated with all of three outcomes compared to within normal range group; 
death through day 180, HF rehospitalization through day 60, and death or cardiovascular or renal rehospitalization 
through day 60. In multivariable Cox regression models, serum albumin (for the outcome of death through day 180 
and death or cardiovascular or renal rehospitalization through day 60) and age (for the outcome of death or 
cardiovascular or renal rehospitalization through day 60) were stratified due to violation of proportional hazard 
assumption. Proportional hazard assumptions were not violated in the stratified model. Higher than normal range 
of BUN/Creatinine ratio was associated with significantly higher risks for death through day 180 and death or 
cardiovascular or renal rehospitalization through day 60 in multivariable analyses, even after adjustment for the 
clinical model including both BUN and creatinine (Table 2). There was no significant interaction between higher 





Figure 3. Kaplan-Meier survival curves for all-cause mortality within 180 days for the three different groups in acute 
heart failure patients (PROTECT) 
 




  Univariate Cox   Adjusted model* 
  HR  95%CI 
P 
value 
  HR  95%CI 
P 
value 
Death through Day 180 340 (17.4)                 
BUN/Creatinine ratio within normal 
range  
191 (13.2)  1 (Reference)  1 (Reference) 
BUN/Creatinine ratio lower than 
normal range 
0   - - -   - - - 
BUN/Creatinine ratio higher than 
normal range  
149 (30.9)  2.66 2.14-3.29 <0.001  1.86 1.29-2.66 <0.001 
Death or Cardiovascular or Renal 
Rehospitalization through Day 60 
558 (28.5)                 
BUN/Creatinine ratio within normal 
range  
360 (24.9)  1 (Reference)  1 (Reference) 
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BUN/Creatinine ratio lower than 
normal range 
5 (17.9)   0.69 0.28-1.66 0.405   0.99 0.39-2.53 0.997 
BUN/Creatinine ratio higher than 
normal range 
193 (40.0)  1.82 1.53-2.16 <0.001  1.37 1.03-1.82 0.03 
HF Rehospitalization through Day 60 285 (14.6)                 
BUN/Creatinine ratio within normal 
range 
190 (13.1)  1 (Reference)  1 (Reference) 
BUN/Creatinine lower than normal 
range 
2 (7.1)   0.52 0.13-2.05 0.35   0.74 0.18-3.14 0.689 
BUN/Creatinine higher than normal 
range 
93 (19.3)   1.53 1.20-1.96 <0.001   1.23 0.81-1.86 0.337 
* Adjusted for age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, sodium, log 
blood urea nitrogen, log creatinine and albumin 
 
When BUN/Creatinine ratio group was added to clinical model, significant NRI and IDI were observed for outcome 
of death through 180 days (NRI: 0.27, P<0.001, and IDI: 0.01, P<0.001), death or cardiovascular or renal 
rehospitalization through day 60 (NRI: 0.15, P=0.003, and IDI: 0.003, P=0.016), but not for heart failure 
rehospitalization (NRI: 0.08, P=0.228, and IDI: 0.00, P=0.865).  
The PREVEND cohort did not include subjects older than 75 years but 37.6% of the PROTECT cohort in our study 
were over 75 years old. We therefore performed a sensitivity analysis only for the PROTECT study cohorts aged 75 
years or younger. In Cox regression analysis, higher than normal range of BUN/Creatinine ratio group was 
consistently associated with a higher risk for both outcomes of death through 180 days and death or cardiovascular 
or renal rehospitalization through day 60 in both univariate and multivariable analysis (Supplemental Table 2). P 
value for interaction between age above/below 75 years and BUN/Creatinine ratio group was not significant for 
any of outcomes (all P value > 0.50).   
 
Discussion 
In the present study, we showed several novel findings regarding BUN/Creatinine ratio both in the general 
population and in patients who were hospitalized for acute HF. In the general population, there was a wide variation 
in BUN/Creatinine ratio. BUN/Creatinine ratio increased with age and more in females compared with males. 
BUN/Creatinine ratio was higher in acute HF patients compared with the general population, and a quarter of them 
showed higher than normal range of BUN/Creatinine ratio. Higher than normal range of BUN/Creatinine ratio was 
associated with more severe HF symptoms, and also associated with higher mortality even after adjustment for 
other prognostic factors including creatinine and BUN.   
 
BUN to creatinine ratio in normal subjects 
We evaluated subjects without cardiovascular comorbidities in PREVEND and found that age and sex were 
significant determinants of BUN/Creatinine ratio. The age-related increase in BUN/Creatinine ratio can be partially 
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explained by difference in age-related change of these two biomarkers. Even if age-associated glomerular function 
impairment affects both creatinine and BUN equally, the magnitude of increase in creatinine, but not in BUN, might 
be attenuated by a decrease in muscle mass with increasing age 21. This hypothesis is supported by the recent study 
which investigated the difference in age-related change in handling between creatinine and BUN22. In this study, 
only serum BUN but not creatinine increased with age, and they also showed this difference was derived primarily 
from smaller age-related reduction in production of BUN compared to creatinine. In other words, age-related 
decrease in clearance exceed age-related reduction in production only in BUN, but not creatinine, and this 
difference is a main driver of age-related increase in BUN/Creatinine ratio. Another study also showed the increase 
in BUN/Creatinine ratio with age in normal subjects23.      
 
We also found that there was a significant interaction between age and sex on BUN/Creatinine ratio. With 
increasing age, BUN/Creatinine ratio was increased more in females than males, and this sex difference in age-
related increase in BUN/Creatinine ratio is derived primarily from the difference in the age-related increase in BUN 
levels rather than creatinine. This finding can potentially be partially explained by a sex difference in change in 
protein turnover with age. Two recent studied focusing on elderly females showed higher protein synthesis rate 
compared to males, despite the females having less muscle mass than males24, 25. Interestingly, this difference in 
protein turnover was not shown between middle-aged males and females26. These findings imply that sex 
differences in protein turnover do not occur until later in life. Indeed, high BUN/Creatinine ratio was shown in 
subjects who are over the age of 65 and without previously detected medical disorders27, but not in children (mean 
age 12.4 years old)28. These findings support our hypothesis regarding sex difference in age-related change in 
BUN/Creatinine ratio. Although further investigations are needed to clarify the pathophysiological background of 
BUN/Creatinine ratio in normal subjects, our results clearly showed the importance of taking age and sex into 
account when we evaluate BUN/Creatinine ratio.  
 
BUN to creatinine ratio in acute heart failure 
The reabsorption process of BUN in the tubules is directly and indirectly potentiated by activation of renin-
angiotensin-aldosterone activity, sympathetic nervous activity, and arginine-vasopressin activity3. Therefore, BUN 
is suggested as an integrated marker of renal function and neurohormonal activation. In fact, BUN outweighed 
creatinine (or estimated glomerular filtration rate) in prognostic ability and appeared to be one of the most 
powerful predictors of prognosis in HF patients18, 29. Moreover, this physiological background forms the basis of 
BUN/Creatinine ratio as a maker of renal neurohormonal activity and many studies have reported an association 
between BUN/Creatinine ratio and hemodynamics and/or prognosis independently from creatinine or estimated 
glomerular function in HF4, 5 Howevere these association were not found independent of an association with BUN, 
suggesting that BUN may be the real driving force of the association.  
 
In line with this pathophysiological background, the group with higher than normal range of BUN/Creatinine ratio 
showed associations with some indices of neurohormonal activity. In 427 patients enrolled in the DOSE and 
CARRESS-HF trials, low blood pressure, low ejection fraction, low sodium and high BUN levels are associated with 
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the above-median levels of plasma renin or plasma aldosterone of renin-angiotensin-aldosterone activity30. This 
finding supports our speculation that higher than normal range of BUN/Creatinine ratio represents highly activated 
neurohormonal status in AHF patients.   
 
Higher than normal range of BUN/Creatinine ratio at baseline was not associated with WRF in our cohort. This is in 
contrast to the current concept of linking between RAAS activation and WRF in AHF patients. However, limited data 
have directly shown this association in AHF and some studies showed disassociation. Takaya et al. showed baseline 
BUN/Creatinine ratio in AHF was not associated with acute kidney injury within 48 hours defined by serum 
creatinine increase ≥0.3 mg/dL or 50% from baseline9. In another AHF study, the incidence of WRF was similar in 
AHF patients with high/low plasma renin and aldosterone activity at baseline30. These findings imply a complex and 
multifactorial pathophysiological background of WRF in AHF patients.  
 
We found that higher than normal range of BUN/Creatinine ratio was associated with high mortality independently 
from both BUN and creatinine. Although several studies have shown that high BUN/Creatinine ratio is associated 
with worse outcome in patients with HF, no study showed the prognostic significance of BUN/Creatinine ratio 
independently from BUN4-10.  
 
In the present study, we found BUN/Creatinine varied widely even in the general population, probably due to the 
influence of non-renal factors on both creatinine and BUN. BUN/Creatinine ratio was significantly higher in patients 
with AHF than normal subjects in line with the current concept; however, BUN/Creatininne ratio was still within 
the predicted 95% interval in more than 70% of AHF patients. This implies that it is difficult to evaluate 
BUN/Creatinine ratio just by itself and without any reference. Our study results also showed that BUN/Creatinine 
ratio was an age- and sex-dependent variable. According to these results, we evaluated BUN/Creatinie ratio based 
on prediction interval after incorporating these properties. We speculate that this approach makes it possible to 
identify the AHF patient whose BUN/Creatinine ratio is irrationally high and at high risk of worse prognosis.   
 
Limitations  
This study has several important limitations. This study was performed retrospectively, and some subjects with 
missing BUN/Creatinine data were excluded in both PROTECT and PREVEND datasets. Additional factors that can 
affect BUN/Creatinine ratio including corticosteroid and some antibiotics use were not assessed. Both datasets 
primarily consist of Caucasian subjects and our study results might not be applicable to other ethnicities. We used 
the PREVEND dataset after excluding patients with cardiovascular comorbidity to derive general cohort and to 
estimate BUN/Creatinine from age and sex; however, this may not be sufficient to determine normal range of 
BUN/Creatinine ratio. By design, PREVEND dataset was enriched for subject with increased albumin excretion in 
urine. We performed a weighted analysis to correct this; however, there was a possibility that study design affected 
our results In the PROTECT study, only AHF patients with mild renal dysfunction were included and external 
validation for a wider cohort of AHF patients is not included in the present analysis. Only up to 180 day mortality 
and 60 days rehospitalization data were available by study design and impact of higher than normal range of 
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BUN/Creatinine ratio on long-term prognosis remains to be investigated. As this is an AHF cohort, very few patients 
were classified as lower than normal range of BUN/Creatinine ratio and our analysis did not have enough power to 
evaluate prognostic significance of this group. 
 
Conclusions 
BUN/Creatinine ratio was an age- and sex-related variable, and it varied widely in the general population. 
BUN/Creatinine ratio was higher in patients with AHF compared to the general population, and a quarter of AHF 
patients had higher than normal range of BUN/Creatinine ratio. In AHF patients, higher than normal values of 
BUN/Creatinine ratio were associated with worse outcome and provided additive prognostic information on top of 
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Age 44±11 56±11 <0.001 
Male gender 2012 (45) 1956 (56) <0.001 
Race (%)    
Caucasian 4226 (95) 3331 (96) 0.006 
Negroid 48 (1) 31 (1)  
Asian 109 (2) 57 (2)  
Other 72 (2) 35 (1)  
BMI 25±4 28±4 <0.001 
Systolic blood pressure (mmHg) 118±11 142±21 <0.001 
Diastolic blood pressure (mmHg) 70±7 80±10 <0.001 
Heart rate (bpm) 68±10 70±11 <0.001 
Smoking history (within 1year) 1760 (39) 1250 (36) 0.002 
Stroke history  19 (0.4) 54 (1.6) <0.001 
Creatinine (mg/dl) 0.90 (0.81-1.01) 0.96 (0.85-1.07) <0.001 
BUN (mg/dl) 14 (12-16) 15 (13-18) <0.001 
Cholesterol (mg/dl) 199 (178-220) 244 (213-271) <0.001 
Glucose (mg/dL) 83 (76-88) 88 (81-99) <0.001 
hs-CRP (mg/L) 0.9 (0.4-2.3) 1.8 (0.9-3.9) <0.001 
NT-proBNP (pg/mL) 32.9 (15.2-60.9) 46.0 (20.0-98.7) <0.001 
UAE (mg/24h) 8.0 (5.8-12.6) 12.5 (7.4-29.6) <0.001 
BUN/Creatinine ratio 15.0 (13.0-17.6) 15.8 (13.4-18.7) <0.001 
BMI, body mass index; BUN, blood urea nitrogen; BUN/Creatinine, blood urea nitrogen to creatinine; hs-CRP, high-















Supplemental Table 2. Cox regression analysis for outcomes in acute heart failure patients age 75 or below 
(PROTECT) 
Outcomes 
Univariate Cox   Adjusted for clinical model* 
HR  95%CI P value   HR  95%CI P value 
Death through Day 180 
BUN/Creatinine ratio within 
normal range  
1 (Reference)  1 (Reference) 
BUN/Creatinine ratio lower than 
normal range 
- - -   - - - 
BUN/Creatinine ratio higher than 
normal range  
2.77 2.06-3.71 <0.001  2.09 1.27-3.45 0.003 
Death or Cardiovascular or Renal Rehospitalization through Day 60 
BUN/Creatinine ratio within 
normal range  
1 (Reference)  1 (Reference) 
BUN/Creatinine ratio lower than 
normal range 
0.65 0.21-2.04 0.462   0.84 0.25-2.82 0.78 
BUN/Creatinine ratio higher than 
normal range  
1.86 1.50-2.32 <0.001  1.35 0.94-1.93 0.100 
HF Rehospitalization through Day 60 
BUN/Creatinine ratio within 
normal range  
1 (Reference)  1 (Reference) 
BUN/Creatinine ratio lower than 
normal range 
0.81 0.20-3.29 0.770   1.17 0.26-5.27 0.837 
BUN/Creatinine ratio higher than 
normal range  
1.54 1.13-2.09 0.006   1.06 0.64-.176 0.830 
*Adjusted for age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, sodium, log 
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Over half of all admitted acute decompensated heart failure (ADHF) patients have renal failure. Although diuretics 
represent the mainstay of treatment strategy even in this population, there are unmet needs for safer and more 
effective treatment. Tolvaptan is a vasopressin-2 receptor antagonist, and we hypothesized that adding tolvaptan 
to standard diuretic therapy would be more effective in ADHF patients with renal function impairment. 
 
Methods 
The Answering question on tolvaptan’s efficacy for patients with acute decompensated heart failure and renal 
failure (AQUAMARINE) is a multicenter, randomized controlled clinical trial, which will enroll 220 patients from 17 
hospitals in Japan. ADHF patients whose estimated glomerular filtration rate is above 15 and below 60 mL/min/1.72 
m2 will randomly assign within 6 h after admission to usual care with furosemide or tolvaptan add-on therapy. 
Primary endpoint is achieved urine output within 48 hours. Secondary endpoints include dyspnea relief measured 
by 7-points Likert scale, incidence of worsening renal function, dose of furosemide used within 48 h, and changes 
of brain natriuretic peptide. 
 
Conclusion 
This study is the first multicenter study in Japan to evaluate clinical effectiveness of tolvaptan add-on therapy in 
ADHF patients with renal failure. Results of this study address treatment strategy of this high-risk population (UMIN 
Clinical Trial Registry Number: UMIN000007109).    
 














Acute decompensated heart failure (ADHF) is one of the most common causes of hospitalization and death in 
patients with cardiovascular disease. The rate of admission due to ADHF has more than doubled in the past 30 
years in United States [1]. According to the Japanese Nationwide Registry of Acute Heart Failure (ATTEND registry), 
the in-hospital mortality rate is 6.4% and median duration of admission is 21 days in Japan [2]. The main problem 
of ADHF is fluid retention, clinically expressed by systemic and pulmonary congestion, and so intravenous loop 
diuretics have been the mainstay form of treatment for ADHF despite a lack of robust clinical evidence. 
Renal function deterioration in ADHF, which is commonly described as “Cardiorenal Syndrome Type 1,” is very 
common in daily practice [3]. Among patients included in the ADHERE registry, the estimated glomerular filtration 
rate (eGFR) at admission was below 60 mL/min/1.73 m2 in 63.6% of all ADHF patients. The mean serum creatinine 
clearance in Japanese patients was 1.43 mg/dL in the ATTEND registry [2]. As the mean age of registered patients 
was reported as 73.0 years old, we estimated that over half of all patients have renal dysfunction at admission due 
to ADHF even in Japan. 
One of the clinical issues of this renal impairment is a reduced response to diuretics (i.e., diuretic resistance). This 
phenomenon is multifactorial and poorly understood, and therefore there is no proven treatment strategy for this 
population. Diuretic refractoriness is influenced mostly by renal function and low-dose diuretic administration [4, 
5]. Therefore, we commonly up-titrate the dose of diuretics in patients with impaired renal function. However, this 
direction of therapy may fall into a vicious cycle: high-dose diuretic use is associated with activation of the renin–
angiotensin–aldosterone system and sympathetic nervous system, both of which lead to reduce renal blood flow 
[6, 7].  
Recently, several non-peptide vasopressin receptor antagonists have entered clinical development, including 
tolvaptan. Tolvaptan is an oral, once-daily, vasopressin-2 receptor antagonist. In contrast to furosemide, tolvaptan 
has been shown to achieve urine output without decreasing renal blood flow in heart failure patients [8]. Moreover, 
tolvaptan seems not to activate the sympathetic nervous system and the renin–angiotensin–aldosterone system 
[9].   
The Answering question on tolvaptan’s efficacy for patients with acute decompensated heart failure and renal 
failure (AQUAMARINE) is a randomized control trial to evaluate the hypothesis that we can treat patients with ADHF 
and renal failure more effectively and safely by adding tolvaptan to standard diuretic therapy compared to 
conventional treatment strategies.  
 
Methods 
Study Design  
AQUAMARINE is a multicenter, prospective, randomized, controlled trial to compare conventional therapy with 
tolvaptan add-on therapy in ADHF patients. This study is being performed at 17 hospitals, consisting of 3 university 









coordinated by the Data Coordinating Center at Kameda Medical Center in Kamogawa, Chiba, Japan.  
 
Objectives 
The primary objective of AQUAMARINE is to determine the clinical effectiveness of tolvaptan add-on therapy in 
patients with ADHF and renal failure, which is defined as eGFR below 60 mL/min/1.73 m2, compared to 
conventional therapy. The secondary objectives are to evaluate the clinical safety of using tolvaptan in ADHF and 
renal failure patients.  
 
Patient population, inclusion and exclusion criteria 
This study received approval from the institutional review board/ethics committee at each site and was conducted 
in accordance with the principles of the Declaration of Helsinki. Written informed consent is obtained from all 
patients before including and randomizing. Only patients admitted to hospital with primary diagnosis of ADHF are 
considered eligible for enrollment. We include only patients with renal dysfunction at the point of admission 
(defined as eGFR below 60 mL/min/1.73 m2 on the day of inclusion) and apparent signs of congestion: jugular 
venous distention, pitting edema, or dyspnea. eGFR is calculated by using Modification of Diet in Renal Disease 
Study equation coefficients modified for Japanese [10]. Inclusion and exclusion criteria are listed in Table 1. 
 
Table 1. Inclusion and Exclusion criteria 
Inclusion and Exclusion Criteria 
Inclusion Criteria 
1. 20 ≤Age< 85 years old  
2. Admitted to hospital with a primary diagnosis of ADHF 
3. Have at least one sign of congestion (peripheral edema, 
pulmonary congestion, pleural effusion, jugular venous distention, 
orthopnea) 
4. 15 ≤ eGFR ≤ 60 mL/min/1.73 m2 
 
Exclusion Criteria 
1. Requiring mechanical circulatory support  
2. Consciousness disturbance  
3. Hypernatremia (serum Na at admission > 147 mEq/l) 
4. Volume depletion  
5. Cardiac shock 
6. Allergy or contraindication for tolvaptan 
7. Acute coronary syndrome 









ADHF, acute decompensated heart failure; eGFR, estimated glomerular filtration rate 
 
Randomization and intervention 
Eligible patients who agree to participate in the study are randomized in a one-by-one fashion using a web-based 
randomization system to receive tolvaptan add-on therapy (15 mg once daily for 2 days in addition to conventional 
therapy) or conventional therapy only within 6 h of admission (Figure 1). Increasing or decreasing the dose of 
tolvaptan in the study period (2 days) is not allowed. After the study period, the clinical decision regarding whether 
to continue or discontinue tolvaptan is left to each attending physician. In conventional therapy for ADHF, whether 
to use standard heart failure drugs, including angiotensin-converting-enzyme inhibitors, angiotensin receptor 
















The primary endpoint is urine output within 48 h after randomization. Secondary endpoints include incidence of 
worsening of renal function (0.3 mg/dl or 50% serum creatinine rise from baseline within 48 h) and dose of 
furosemide used within 48 h after randomization. Patients’ self-reported symptoms (seven-point Likert scale of 
change compared with baseline) are also measured and recorded at 6, 12, 24, and 48 h after randomization, and 
dyspnea relief is also compared between the two groups. Changes in blood urea nitrogen, serum creatinine, eGFR, 
brain natriuretic peptide, serum sodium, serum potassium, signs of congestion, and body weight are also measured 
as secondary endpoints. Serum creatinine, blood urea nitrogen, sodium, and potassium are measured at baseline 
and 6, 12, 24, and 48 h after randomization. Brain natriuretic peptide and body weight are measured at baseline 
and 48 h after randomization. Any adverse outcome, including induction of mechanical ventilation, and 
requirement of any renal replacement therapy are also included as secondary endpoints.  
 
Statistical analysis 
According to previous observational research, the standard deviation of urine output within 48 h after admission 
is 2350 ml [11]. Therefore, we decided a sample size of 110 patients per treatment arm to provide 85% power for 
detecting a difference between treatment groups in urine output within 48 h of 1000 ml after making allowance 
for 8% dropout after randomization. 
 
The primary endpoint will be analyzed by the two-sample t-test. The secondary endpoints will be analyzed by the 
two-sample t-test (continuous outcome) and the chi-squared test (categorical outcomes). 
 
Discussion 
AQUAMARINE is designed to evaluate the clinical effectiveness of tolvaptan add-on therapy for patients with ADHF 
and renal failure. Treatment of this cohort is very challenging not only due to diuretic resistance, but also the 
greater length of hospital stay, readmission, and high in-hospital mortality rate have been reported in previous 
studies [12-14]. However, as a considerable proportion of ADHF patients have renal failure at the time of admission, 
it is necessary to search for a better treatment strategy. In some cases, intravenous diuretics for this population 
may lead to further worsening of renal function throughout direct and indirect adverse effects on the kidney. There 
is, however, a dilemma that ADHF patients require decongestion as soon as possible, and diuretics are prerequisites 
for decongestion in ADHF patients even in renal failure. Tolvaptan has emerged as a new-class of diuretic differing 
from furosemide in its favorable effects on renal blood flow, neurohormones, and blood pressure [8, 9, 15, 16]. 
These factors play crucial roles in renal function even in heart failure. Therefore, we hypothesize that tolvaptan 
would be especially effective in ADHF and renal failure patients. 
The effects of tolvaptan in ADHF patients were evaluated in a double-blind randomized clinical trial (EVEREST). In 









short-term, but no prognostic benefit in medium-term outcome [17, 18]. However, there were some differences in 
study design between EVEREST and AQUAMARINE: dose and duration of tolvaptan use (30 mg and minimum of 60 
days vs. 15 mg and 2 days), time to randomization (within 48 h vs. 6 h), and patients’ renal function. Time to 
randomization in clinical trials regarding ADHF is of primary importance. To date, clinical trials concerning ADHF, 
including EVEREST, enrolled patients relatively late (24 – 48 h after admission) in the acute phase [17, 19, 20]. 
However, dyspnea was improved in 76% of ADHF patients within 6 h [21]. This suggests that the adequate time 
window for enrolling patients in clinical trials to evaluate the effectiveness of treatments in ADHF is the very early 
phase [22], and this is why we decided a time window of within 6 h for enrollment in our trial. The dose of tolvaptan 
used in our study (15mg) is lower than that commonly used in US (30mg). However, in phase II study which was 
conducted in Japanese HF patients, all three dose (15mg, 30mg, and 45mg) decreased body weight and improve 
the signs of volume overload, and these effects were not dose-dependent [23]. This is the rationale behind the 
choice of 15mg dose in this study. 
In conclusion, AQUAMARINE is a multicenter, open-label, randomized trial for evaluating the clinical effectiveness 
of tolvaptan as additive therapy in the acute phase of ADHF in patients with renal failure. The results of this study 
will be beneficial for determining the appropriate treatment strategies for ADHF patients.   
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More efficacious and/or safer decongestive therapy is clearly needed in acute heart failure (AHF) patients 
complicated by renal dysfunction. We tested the hypothesis that adding tolvaptan, an oral vasopressin-2 receptor 
antagonist, to conventional therapy with loop diuretics would be more effective treatment in this population. 
 
Methods and Results 
A multicenter, open-label, randomized control trial was performed, and 217 AHF patients with renal dysfunction 
(estimated glomerular filtration rate 15 – 60 mL/min/1.73 m2) were randomized 1:1 to treatment with tolvaptan 
(n = 108) or conventional treatment (n = 109). The primary endpoint was 48-hour urine volume. The tolvaptan 
group showed more diuresis than the conventional treatment group (6464.4 vs. 4999.2 mL, P < 0.001) despite 
significantly lower amounts of loop diuretic use (80 mg vs. 120 mg, P < 0.001). Dyspnea relief was achieved 
significantly more frequently in the tolvaptan group at all time points within 48 hours except 6 hours from 
enrollment. The rate of worsening of renal function (≥ 0.3 mg/dL increase from baseline) was comparable between 
tolvaptan and conventional groups (24.1% vs. 27.8%, respectively; P = 0.642).  
 
Conclusions 
Adding tolvaptan to conventional treatment achieved more diuresis and relieved dyspnea symptoms in AHF 
patients with renal dysfunction. 
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Acute heart failure (AHF) is one of the most important causes of hospitalization worldwide, and the prognosis of 
this disease remains unsatisfactory1-3. Renal dysfunction, which is usually defined as an estimated glomerular 
filtration rate (eGFR) < 60 mL/min/1.73 m2, is highly prevalent in AHF patients4, 5. Treatment of AHF patients 
complicated with renal dysfunction is still challenging because this population may be relatively refractory to 
treatment with loop diuretics, which may in themselves aggravate renal dysfunction. Patients with AHF and renal 
dysfunction have prolonged hospital stays, high in-hospital and long-term mortality rates6, 7. No therapy thus far 
tested has improved upon either short-term or long-term outcomes in these patients, including most recently 
ultrafiltration, standard and low-dose nesiritide, and low-dose dopamine8, 9. To date, therefore, there is no therapy 
yet proven to be either more efficacious or safe in this patient population when compared to loop diuretics. Given 
the high prevalence of renal dysfunction and the poor outcomes in these patients, there remains an unmet need 
to develop a new treatment strategy. 
Tolvaptan is an oral, nonpeptide, selective vasopressin-2 receptor antagonist that acts on the distal portion of the 
nephron, blocking the interaction of the antidiuretic hormone arginine vasopressin and the V2 receptor. This 
prevents the activation of the aquaporin system, impairs the ability of the kidney to reabsorb water, and as a result 
causes an increase in free water excretion. Tolvaptan has been shown to be safe and effective in the correction of 
euvolemic and hypervolemic hyponatremia including that seen in patients with heart failure10. The efficacy of 
tolvaptan as a treatment for AHF was evaluated in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome 
Study With Tolvaptan (EVEREST) trial11, 12. However, the EVEREST study did not specifically target AHF patients 
complicated with renal dysfunction. In other studies, tolvaptan showed beneficial effects on renal function, such 
as maintenance of renal blood flow and no activation of the sympathetic nervous and renin-angiotensin-
aldosterone systems compared to loop diuretics13. In a previous small retrospective study, we reported that 
addition of tolvaptan to conventional therapy yielded more urine with less furosemide use and less worsening of 
renal function (WRF)14. We therefore designed the AQUAMARINE study to evaluate the effects of tolvaptan on 
decongestion, clinical signs and symptoms, and renal function when added to conventional therapy in patients with 





The AQUAMARINE study was a prospective, multicenter, randomized, open-label, parallel group study to evaluate 
the short-term efficacy of adding tolvaptan to conventional therapy for treatment of AHF. The study background 
and design have been published previously15. Briefly, AHF patients admitted to hospital and complicated with renal 
dysfunction (eGFR 15 – 60 mL/min/1.73 m2 by simplified Modification of Diet in Renal Disease estimated 









hours from admission at 14 hospitals across Japan. The diagnosis of heart failure was based on the Framingham 
criteria, but at least one of the following five signs or symptoms of congestion was required: peripheral edema, 
pulmonary congestion, pleural effusion, jugular venous distension, or orthopnea. Key exclusion criteria included 
diagnosis of acute coronary syndrome on admission, hypernatremia defined by serum sodium > 147 mEq/L, and 
chronic hemodialysis. 
All enrolled patients were randomized 1:1 in an open fashion to receive conventional therapy or tolvaptan add-on 
therapy by an automated web-based randomization system created by a third-party company (Mebix, Inc., Tokyo, 
Japan). We applied a minimization procedure when randomizing using eGFR < 30 mL/min/1.73 m2, blood pressure 
> 140 mmHg, and age > 60 years old as stratification factors. The patients allocated to the tolvaptan group received 
oral tolvaptan (15 mg/day) for 2 days; the day of enrollment and the following day. In addition, physicians were 
permitted to treat the patients with any conventional therapy at their discretion. Fluid restriction was also 
permitted at the physician’s discretion during study period. The choice of conventional therapy for AHF, i.e. 
standard heart failure drugs, including angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, 
vasodilators, beta-blockers or digoxin, is left to the attending physician. After 2 days of mandatory tolvaptan 
treatment in the tolvaptan group, physicians determined whether to continue tolvaptan or not according to each 
patient’s status. Similarly, treatment with tolvaptan was prohibited for the first 2 days in the patients allocated to 
the conventional group. The investigation conforms with the principles outlined in the Declaration of Helsinki. The 
ethics committee at each center approved the study, and all patients provided written informed consent. 
 
Endpoints 
The primary endpoint was amount of urine output within 48 hours of randomization. The secondary endpoints 
were: (1) incidence of WRF defined as an increase in serum creatinine (≥0.3 mg/dL increase from baseline) at 
various pre-specified time points (6, 12, 24, and 48 hours from randomization); (2) moderate or marked 
improvement of dyspnea from baseline according to patient-reported 7-point Likert scale measured at 6, 12, 24, 
and 48 hours from enrollment; (3) amount of furosemide-equivalent loop diuretics used within 48 hours; (4) 
changes in blood pressure, heart rate, serum sodium, serum potassium, serum creatinine, eGFR, and blood urea 
nitrogen at 6, 12, 24, and 48 hours from enrollment; (5) changes in brain natriuretic peptide (BNP) and body weight 
from baseline to 48 hours; (6) incidence of any adverse events; and (7) combined endpoint of all cause death and 
heart failure rehospitalization within 90 days.  
 
Statistical analysis 
A sample size of 110 patients for each group was decided based on our previous study data to detect a difference 
of 1000 mL in urine output within 48 hours between the two groups with 85% power and 5% alpha-error, while 
allowing for an 8% drop-out rate14. 
Pre-specified subgroup analyses were conducted for patients with age ≥ 75 years old, heart failure with preserved 
ejection fraction (HFpEF) (≥ 50%), non-ischemic etiology, systolic blood pressure (SBP) > 140 mmHg, eGFR < 30 









median of BUN/creatinine ratio. 
 
The primary outcome as well as other two-group comparisons of continuous outcomes were performed with 
Student’s t test for independent variables and paired t test for paired variables. For non-normally distributed 
continuous outcomes, Wilcoxon’s rank sum test was used for independent variables and Wilcoxon’s signed rank 
test for paired variables. Categorical outcomes were tested with Pearson’s chi-squared test or Fisher’s exact test. 
For repeatedly measured outcomes, linear mixed effect models were used to examine the interactions between 
these variables and time to test differences in trajectories over time. All treatment comparisons were performed 
according to the intention-to-treat principle. Two-tailed P < 0.05 was taken to indicate statistical significance for all 




A total of 220 patients were enrolled between December 2011 and January 2015. After randomization, one patient 
in the tolvaptan group and one patient in the conventional group withdrew their consent and data were missing 
for one patient in the tolvaptan group. Therefore, after excluding these three patients, 217 patients were finally 
included in the final analysis (Figure 1). The baseline characteristics of the patients were similar between both 
groups (Table 1). The median age of the patients was 75 years (interquartile range [IQR], 68 – 81 years), and 64.9% 
were male. The median left ventricular ejection fraction was 44.5%, and 82 (37.8%) of the whole cohort had left 
ventricular ejection fraction ≥ 50%. The reported etiologies of participants were as follows: ischemic etiology, 60 
(27.6%); cardiomyopathy, 69 (31.8%); hypertensive AHF, 50 (23.0%); valvular disease, 32 (14.7%); and others, 25 
(11.5%) patients. The mean eGFR at baseline was 40.5 mL/min/1.73 m2, and 57 (26.3%) patients had eGFR < 30 
mL/min/1.73 m2. The median time from admission to randomization was 1 hour, and 41.4% of patients were 










Figure 1. Study flow chart including number of patients who underwent assignment.   
AHF, acute heart failure 
 
Table 1. Patient characteristics 
Variables 
Conventional Group  
(n = 109) 
Tolvaptan Group 
(n = 108) 
Age (years) 72.95 ± 10.24 72.99 ± 8.90 
Male (%) 69 (63.3) 72 (66.7) 
Systolic blood pressure (mmHg) 142.1 ± 28.1 145.8 ± 32.9 
Diastolic blood pressure (mmHg) 82.4 ± 20.2 83.2 ± 24.0 
Heart rate (bpm) 88.6 ± 23.4 94.2 ± 27.3 
LVEF (%) 46.8 ± 16.4 45.4 ± 18.1 
HFpEF (%) 42 (39.3) 40 (37.4) 
NYHA III/IV (%) 69 (63.3) 79 (73.1) 
Medical History (%)   
HF admission 47 (43.1) 48 (44.4) 
Hypertension 83 (76.1) 82 (76.6) 
Diabetes 54 (49.5) 42 (38.9) 
Dyslipidemia  47 (43.1) 45 (41.7) 
Atrial fibrillation  55 (50.5) 60 (55.6) 
Smoking (Current or Ex) 54 (51.4) 57 (53.8) 
Drugs at admission (%)   









Furosemide equivalent loop diuretic 
dose 
among users (mg) 
40.0 [20.0 – 60.0] 30.0 [20.0 – 45.0] 
ACE-I/ARB  41 (37.6) 45 (41.7) 
Beta blocker 43 (39.4) 41 (38.0) 
Aldosterone antagonist 27 (24.8) 19 (17.6) 
Digoxin 5 (4.6) 7 (6.5) 
Furosemide equivalent amount of 
loop  
diuretics used before randomization 
(mg) 
20.0 [20.0 – 20.0] 20.0 [20.0 – 20.0] 
Time to Randomization (hours) 1.0 [0.0 – 2.0] 1.0 [0.0 – 3.0] 
IV therapy within 48 hours (%)   
Carperitide 39 (35.8) 41 (38.0) 
Nitrate/ISDN 20 (18.3) 24 (22.2) 
Nicorandil 1 (0.9) 2 (1.9) 
Heparin 49 (45.0) 43 (39.8) 
Dopamine 1 (0.9) 2 (1.9) 
Dobutamine 16 (14.7) 8 (7.4) 
PDEIII inhibitor 0 (0.0) 1 (0.9) 
Lab data   
Creatinine (mg/dL) 1.4 ± 0.5 1.5 ± 0.6 
eGFR (mL/min/1.73 m2) 41.4 ± 13.4 39.5 ± 12.8 
BUN (mg/dL) 25.0 [18.9 – 35.0] 28.0 [20.0 – 37.1] 
Serum sodium (mEq/L) 140.2 ± 3.8 140.5 ± 4.3 
Serum potassium (mEq/L) 4.3 ± 0.7 4.4 ± 0.6 
BNP (pg/mL) 
729.0  
[461.9 – 1482.2] 
939.3  
[532.9 – 1510.8] 
LVEF, left ventricular ejection fraction; HFpEF, heart failure with preserved ejection fraction; NYHA, New York Heart 
Association functional class; HF, heart failure; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; PDE, phosphodiesterase; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; 
BNP, brain natriuretic peptide. 
 
All patient were treated according to allocation. However, four patients took tolvaptan on only 1 day and it was 
discontinued thereafter. The reasons for discontinuation of tolvaptan were hypernatremia in three patients and 
septic shock in one patient. The median duration of tolvaptan treatment in the tolvaptan group was 2 days (IQR: 2 
– 4 days). Continuation, discontinuation, and new prescription of angiotensin converting enzyme inhibitor, 









Supplemental Table 1. There was no significant difference between groups.  
 
Primary endpoint 
Tolvaptan therapy yielded significantly higher 48-hour urine output compared to conventional therapy 
(conventional group, 4997.2 mL; 95% CI, 4598.3 – 5400.0 mL vs. tolvaptan, 6464.4 mL; 95% CI, 5859.1 – 7069.7 mL; 
P < 0.001), and the mean difference between the two groups was 1465 mL (95% CI: 740.7 – 2189.7 mL) within 48 
hours (Table 2). 
 
Table 2. Summary of primary and secondary endpoints  
Outcomes 
Conventional group 
(n = 109) 
Tolvaptan group 
(n = 108) 
P-value 
Primary outcome    
48-hour urine volume (mL) 4997.2 ± 2101.4 6464.4 ± 3173.0 < 0.001 
Secondary outcomes    
Worsening of renal function (%) 30 (27.8) 26 (24.1) 0.642 
Dose of diuretics use within 48 hours (mg) 120 (80 – 180) 80 (40 – 150) < 0.001 
Net fluid loss within 48 hours (mL) 3697.9 ± 2112.0 4700.1 ± 2443.3 0.004 
Change in BNP from baseline to 48 hours (pg/mL) 
-306.1  
(-153.7 to -662.1) 
-285.3  
(-110.7 to -650.9) 
0.602 
Change in body weight from baseline to 48 hours (kg) -1.99 ± 2.17 -3.16 ± 2.66 < 0.001 
Length of hospital stay (day) 14.6 (10.3 – 27.2) 14.2 (8.9 – 20.3) 0.36 
Adverse events (%) 6 (5.5) 10 (9.3) 0.313 
In-hospital death (%) 5 (4.6) 4 (3.7) > 0.99 




The results regarding secondary endpoints are summarized in Table 2. There were no significant differences 
between groups in the incidence of WRF, trajectory of serum creatinine, eGFR, or serum BUN (Figure 2). We also 
evaluated the incidence of WRF in subgroup of HFpEF and heart failure with reduced ejection fraction (HFrEF) 
patients because aggressive fluid removal might lead to subsequent WRF especially in HFpEF17. However, there was 
no difference in incidence of WRF in both HFrEF (26.6% in conventional group vs 23.9% in tolvaptan group, P=0.841) 
and HFpEF patients (29.5% in conventional group vs 24.4% in tolvaptan group, P=0.633). We also checked the 
incidence of WRF within 96 hours, which was not a prespecified endpoint, as a sensitivity analysis. There were 5 
patients crossover from conventional group to tolvaptan group, and 76 patients (70.3%) were treated without 









with conventional group and in 31 patients (28.7%) with tolvaptan group, and there was no statistically significant 
difference (P=0.382).  
 
 











The amount of furosemide-equivalent diuretics used within 48 hours was significantly lower in the tolvaptan group, 
and the median difference between the two groups was 40.0 mg (95% CI: 10.0 – 60.0 mg, P = 0.006). Improvement 
of dyspnea, as defined by moderate or marked improvement from baseline, was significantly more frequent in the 
tolvaptan group at all time points within 48 hours except 6 hours after randomization (Figure 3 and Supplemental 
Table 2). Body weight was significantly decreased in both groups from baseline to 48 hours, but the extent of weight 
loss was significantly greater in the tolvaptan group (mean difference, 1.18 kg; 95% CI, 0.48 – 1.87 kg; P < 0.001). 
As fluid intake was significantly greater in the tolvaptan group than the conventional treatment group (1319.6 ± 
843.3 vs. 1909.3 ± 1300.3 mL, respectively; P < 0.001), net fluid loss was calculated by subtracting total fluid intake 
within 48 hours from total urine volume within 48 hours and compared between the two groups. The tolvaptan 
group showed a significantly greater net fluid loss compared to the conventional treatment group (4700.1 ± 2443.3 
vs. 3697.9 ± 2112.0 mL, respectively; P = 0.005). BNP was significantly decreased in both groups from baseline to 
48 hours (P < 0.001 for both) (Supplemental Table 1), but there was no significant difference in absolute reduction 
of BNP between the two groups (P = 0.60). Similarly, other signs and symptoms of congestion, including edema, 
orthopnea, and pulmonary congestion, improved from baseline to 48 hours in both groups (P < 0.001 for all), and 










Figure 3. Changes in dyspnea and edematous symptoms within 48 hours. (A) The patients reported changes in 
dyspnea from baseline measured on a 7-point Likert scale. (B) Changes in congestive symptoms from baseline to 
48 hours. 
Conv group, conventional group 
 
Heart rate, SBP, and diastolic blood pressure (DBP) decreased from baseline to 48 hours from allocation in both 
groups (Figure 4). There was no significant difference in heart rate trajectory between groups (P = 0.722). However, 
the trajectories of both SBP and DBP were significantly different between the tolvaptan and conventional treatment 
groups (P = 0.005 and P = 0.048, respectively). In addition, we examined the slopes before and after 6 hours by 
linear splines. There were no significant differences in the initial fall in either SBP or DBP between groups during 
the first 6 hours. However, both SBP and DBP stabilized in the tolvaptan group (test for a slope of zero; P = 0.997 
for SBP and P = 0.776 for DBP), whereas blood pressure continued to fall slightly in the conventional group (test for 
a slope of zero; P < 0.001 for both SBP and DBP). There were significant between-group differences in time course 











Figure 4. Blood pressure and heart rate changes within 48 hours (A) Graph showing the mean blood pressure at 
each time point from baseline to 48 hours (B) Graph showing the mean heart rate at each time point from baseline 
to 48 hours. Error bars indicate 95% confidence intervals 
Conv group, conventional group 
 
Similar analyses were performed for repeated measurements of serum sodium and serum potassium to evaluate 
the differences between the two groups (Supplemental Figure 1). There was a significant difference in overall 
trajectory of serum sodium between groups (P < 0.001). Overall, the potassium and BUN trajectories were not 
significantly different between groups (P = 0.382 and P = 0.960, respectively). 
 
We performed pre-specified subgroup analysis and observed consistent results for all subgroups with regard to the 
primary endpoint (Figure 5). There was no significant difference in median length of hospital stay between groups 
(conventional group, 14.6 days; IQR, 10.3 – 27.2 days; tolvaptan group, 14.2 days; IQR, 8.9 – 20.3 days; P = 0.36). 
There were no significant differences in the rate of mechanical ventilation or requirement for any renal replacement 
therapy between groups. Similarly, there were no significant differences in adverse event rate (P = 0.425), all cause 
in-hospital death (P > 0.99), or total adverse events and/or all cause in-hospital death (P = 0.642). During index 
hospitalization, five cases of hypernatremia were reported in the tolvaptan group as adverse events; however, none 
of these cases led to subsequent severe complications and all of these patients recovered spontaneously without 
any treatment after discontinuing tolvaptan. During follow-up period of 90 days, 28 patients were died or 
rehospitalized due to heart failure, but there was no statistical significance between groups in this combined 
outcome (15.0% in conventional group vs. 11.2% in tolvaptan group; P=0.544).   
 
Discussion 
In the present study, when compared with conventional care using loop diuretics, the addition of tolvaptan to such 
care yielded greater net fluid loss and improved dyspnea in AHF patients with moderate to severe renal impairment. 
Despite greater net fluid loss with tolvaptan, renal function was not worsened. These findings are noteworthy as 









of loop diuretics produced more diuresis but also more WRF18. In the ASCEND and ROSE trials adding natriuretic 
peptides and low-dose dopamine, agents expected to improve diuresis and/or improve renal function failed to do 
so when compared with loop diuretics alone9, 19. In the PROTECT trial there was no benefit of an agent specifically 
designed to offset potential renal dysfunction induced by loop diuretics in this high-risk population20. Since renal 
dysfunction in the setting of AHF confers a poor prognosis, possibly in part due to poor response to diuretics and 
subsequent unsuccessful treatment, these findings with tolvaptan are of potential importance and suggest the 
need for larger studies focused on outcomes. 
 
The improvement in net fluid loss, dyspnea relief and preservation of renal function were observed for the entire 
study group and also in those above the median BUN and below the median eGFR subgroups. Renal function in our 
cohort was poorer than in other previous AHF trials targeting this population (DOSE, 54.2 mL/min/1.73 m2; ROSE-
AHF, 42.7 mL/min/1.73 m2; PROTECT, 53 mL/min/1.73 m2)9, 18, 20 and so the results in our lowest eGFR group further 
suggest that tolvaptan may be a promising adjunctive treatment option for AHF patients with moderate to severe 
renal dysfunction. EVEREST investigators reported positive results with tolvaptan retrospectively in a subgroup with 
decreased renal function11, 21, but this was not a prospectively defined subgroup. AQUAMARINE is the first study 
to study tolvaptan prospectively in this group of patients and it confirms the findings from the retrospective analysis 
from EVEREST. 
We also confirmed the consistent favorable effects of tolvaptan on diuresis in all of our other pre-specified 
subgroups, including heart failure with preserved ejection fraction. This finding is an important addition to the 
literature since the only previous large study using tolvaptan in AHF (EVEREST) included only patients with reduced 
left ventricular ejection fraction (≤ 40%). Takei et al. recently showed that aggressive fluid removal with loop 
diuretics may be even more problematic for AHF patients with HFpEF compared to HFrEF17. This could be explained 
by the possibility that the aggressive fluid removal caused by conventional diuretic therapy might have caused 
intravascular volume depletion without refilling from the extravascular space in HFpEF, with subsequent 
impairment of renal function. In our results, WRF incidence was not increased in patient with HFpEF in spite of 
more diuresis in tolvaptan group. This is clearly showed utility of tolvaptan in AHF patients with HFpEF, an 
observation not made in previous trials including EVEREST, and suggests that further trials with this agent should 
not be limited to patients with HFrEF. 
 
The findings in the current study regarding dyspnea relief with tolvaptan also confirm those seen in the first few 
days of therapy in the EVEREST and QUEST trials12, 22. Although the robustness is limited by our open-label nature, 
our findings are in line with other double-blinded studies and support usefulness of tolvaptan in this high-risk 
subgroup given that dyspnea relief is a clinically relevant outcome in AHF patients.  
 
Inconsistent with our previous study14, however, the incidence of WRF in AQUAMARINE was not reduced by 
tolvaptan. The incidence of WRF was low in both groups, our predefined observation period was short, and both 









on renal function. The stability of renal function with greater clinical benefit (symptoms and weight loss) could be 
regarded as a positive rather than a negative finding even at 48 hours, however, since it is possible, that, as seen in 
DOSE, achieving similar results simply by using more loop diuretics might have increased the incidence of WRF.  
The entire issue of the importance of WRF in AHF has grown more complex in the past few years as it has been 
recognized that WRF is a very heterogeneous phenomenon and that the prognostic implications may be affected 
by whether or not the WRF is transient and whether or not it is associated with effective decongestion. Indeed, 
some studies showed that WRF does not adversely affect prognosis in successfully decongested patients23, 24.  
The hemodynamic observations in the present study are also of interest and may relate to the mechanism of action, 
although without cardiac output and systemic vascular resistance measurements interpretation can only be 
speculative. However, we did make very close observations of heart rate, SBP and DBP over 48 hours and we found 
that tolvaptan treatment was associated with better blood pressure maintenance despite greater fluid loss than 
conventional therapy. This is the first time such an observation has been reported and would be consistent with 
the effect of tolvaptan to pull fluid from the extravascular space as opposed to repeated direct depletion of the 
intravascular compartment as one sees with the isosmotic diuresis from furosemide, which might be expected to 
threaten cardiac preload and so cardiac output in vulnerable patients25. Whatever the mechanism this is also a 
favorable effect of tolvaptan because even modest hypotension is associated with poorer outcome and WRF in 
AHF26-28.  
 
Mechanistically, tolvaptan produces diuresis largely by increasing free water diuresis, at least acutely, though over 
time, an increase in urine sodium has also been observed when the drug is given as monotherapy and compared 
with loop diuretic29. This may be due to the effects of an increase in osmolality attendant upon the free water 
diuresis. Since water is freely diffusible the early improvement in dyspnea with tolvaptan seen in this and other 
studies could partially be due to a reduction in lung water, though in the current study we cannot separate this 
possible effect from that of a greater total diuresis. From the standpoint of renal function and safety, it has been 
shown that tolvaptan, presumably because of its primary effect as an aquaretic, does not change the sodium 
concentration at the macula densa, and thereby does not stimulate tubulo-glomerular feedback and/or 
neurohormonal stimulation, both of which have been linked to worsening renal function with loop diuretics. As 
already noted, tolvaptan has been shown in one study in human heart failure to have a favorable effect on renal 
blood flow and GFR as compared to furosemide13. These mechanistic observations, in concert with the current data, 
constitute additional rationale for additional, larger studies with tolvaptan or other V2 antagonists in this high-risk 
patient group.  
However, one note of caution is in order in this regard. A pure V2 antagonist raises osmolality and so stimulates 
AVP secretion, The V1a effects of AVP may be deleterious in any number of ways both acutely and chronically as 
the signaling pathways for this receptor resemble those for angiotensin II. Acutely V2 antagonists as noted have 
been beneficial, but long-term their effects on outcome in heart failure are neutral. Plasma AVP levels were higher 
in patients on tolvaptan in EVEREST and so the debate continues whether offsetting V1-a stimulation from the 









aquaresis/osmotic diuresis30. Conceivably this could occur even in shorter-term studies as well. Therefore, the ideal 
agent for use in a diuretic-sparing AHF regimen might well be a combined V1a-V2 antagonist but other than one 
relatively small study demonstrating the safety and efficacy of this approach data are lacking31, and of course 
introducing a V1a blocker as part of a strategy to look specifically at non-diuretic decongestive strategies would 
introduce another level of complexity in the interpretation of any results. 
 
Our study had several limitations, including primarily its open-label nature, which could have influenced some 
subjective outcome variables, including dyspnea relief, and perhaps more subtly, even objective outcomes if the 
behavior of treating physicians was affected by knowing that adjunctive therapy was being given in one group. We 
did not have data on duration of HF prior to being in this study, and it is possible that the diagnosis was relatively 
new in a substantial number of patients. This might have affected the relatively low usage of guideline 
recommended medications at baseline. Also we had a relatively large number of patients with HFpEF to whom 
these guidelines do not apply. As already noted, this was a study focused on short-term responses so the duration 
of prior therapy would not necessarily have been expected to have a major effect on our results. We did not have 
sufficient power to detect longer term differences in WRF and prognostic endpoints. Regarding the latter we 
acknowledge that since this study was conducted in Japan where length of stay is typically much longer than in the 
US or Europe, any findings related to length of stay or readmission may not be. Relevant to patients treated in these 
countries. And finally, while this study did include patients with both HPrEF and HFpEF (as have other recent studies 
in AHF such as DOSE, CARRESS, ROSE, and ASCEND) the average EF was higher and so strictly speaking whether the 
results could be extrapolated to a patient population more heavily weighted to HFrEF is not known. The similarity 
of our findings to those in the acute phase of EVEREST is, however, reassuring in this regard. 
 
In conclusion, treating patients with AHF and impaired renal function for 48 hours with tolvaptan in addition to 
conventional therapy yielded significantly greater net fluid loss and significantly improved dyspnea without 
worsening renal function. This study when combined with prior trials and mechanistic observations demonstrates 
the potential utility of using a V2 antagonist as part of a loop-diuretic-sparing strategy as an alternative to the 
standard approach of simply increasing conventional diuretic therapy in these high-risk AHF patients.  
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Supplemental Table 1. Medication during the study period 
  Conventional Group Tolvaptan Group P value 
Continuation of the prescribed medication at admission within 48 hours       
ACE-I/ARB 35/41 (85.4%) 38/45 (84.4%) >0.99 
Beta blocker 40/43 (93.0) 33/41 (80.5%) 0.113 
Aldosterone blocker  21/27 (80.8) 15/19 (78.9) >0.99 
New prescription within 48 hours    
ACE-I/ARB 12/68 (17.6) 12/63 (19.0) >0.99 
Beta blocker  5/66 (7.6) 10/67 (14.9) 0.273 
Aldosterone blocker  10/82 (12.2) 5/89 (5.6) 0.177 
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker 
Supplemental Table 2. Body weight and brain natriuretic peptide levels at baseline and 48 hours 
Variable 
Conventional group (n = 109)   Tolvaptan group (n = 108)   
P-value for changes from 
baseline to 48 hours 
(between groups) 
Baseline  48 hours 
P-value  
(Baseline vs. 48 
hours) 
  Baseline  48 hours 
P-value 
(Baseline vs. 48 
hours) 
  











(461.9 – 1482.2) 
361.1  
(173.9 – 694.3) 
 < 0.001   
939.3  
(532.9 – 1510.8) 
468.5  
(260.2 – 772.5) 
 < 0.001   0.60  
Supplemental Table 3. The patients reported changes in dyspnea from baseline measured on a 7-point Likert scale 
Dyspnea with 7-point 
Likert scale 
6 hours  12 hours  24 hours  48 hours 
Conv Tol  Conv Tol  Conv Tol  Conv Tol 
Markedly improved 4 (3.7) 4 (3.7)  1 (0.9) 4 (3.7)  3 (2.8) 6 (5.6)  8 (7.5) 15 (13.9) 
Moderately improved 10 (9.3) 15 (13.9)  19 (17.9) 36 (33.6)  28 (26.2) 49 (45.4)  48 (45.3) 59 (54.6) 
Mildly improved 51 (47.2) 58 (53.7)  58 (54.7) 52 (48.6)  59 (55.1) 38 (35.2)  31 (29.2) 26 (24.1) 
No change 42 (38.9) 30 (27.8)  26 (24.5) 14 (13.1)  17 (15.9) 15 (13.9)  18 (17.0) 7 (6.5) 
Mildly worsened 1 (0.9) 1 (0.9)  1 (0.9) 0  0 0  1 (0.9) 1 (0.9) 
Moderately worsened  0 0  0 1 (0.9)  0 0  0 0 
Markedly worsened  0 0  1 (0.9) 0  0 0  0 0 
Conv, conventional group; Tol, tolvaptan group 
 


















Chapter 6  
 
Early Treatment with Tolvaptan improves diuretic response in acute 
heart failure with renal dysfunction 
 
 
Yuya Matsue  
Jozine M. ter Maaten  
Makoto Suzuki  
Sho Torii  
Satoshi Yamaguchi  
Seiji Fukamizu  
Yuichi Ono  
Hiroyuki Fujii  
Takeshi Kitai  
Toshihiko Nishioka  
Kaoru Sugi  
Yuko Onishi  
Makoto Noda  
Nobuyuki Kagiyama  
Yasuhiro Satoh  
Kazuki Yoshida  
Peter van der Meer  
Kevin Damman  
Adriaan A. Voors  
Steven R. Goldsmith 
 












Background   
Poor response to diuretics is associated with worse prognosis in patients with acute heart failure (AHF). We 
hypothesized that treatment with tolvaptan improves diuretic response in patients with AHF. 
 
Methods  
We performed a secondary analysis of the AQUAMARINE open-label randomized study in which a total of 217 AHF 
patients with renal impairment (eGFR < 60 mL/min/1.73 m2) were randomized to either tolvaptan or conventional 
treatment. We evaluated diuretic response to 40 mg furosemide or its equivalent based on two different 
parameters: change in body weight and net fluid loss within 48 hours.  
 
Results  
The mean time from patient presentation to randomization was 2.9 hour. Patients with a better diuretic response 
showed greater relief of dyspnea and less worsening of renal function. Tolvaptan patients showed a significantly 
better diuretic response measured by diuretic response based both body weight [−1.16 (IQR, −3.00 to −0.57) kg/40 
mg vs. −0.51 (IQR, −1.13 to −0.20) kg/40 mg; P < 0.001] and net fluid loss [2125.0 (IQR, 1370.0–3856.3) mL/40 mg 
vs. 1296.3 (IQR, 725.2–1726.5) mL/40 mg; P < 0.001]. Higher diastolic blood pressure and use of tolvaptan were 
independent predictors of a better diuretic response. 
 
Conclusions  
Better diuretic response was associated with greater dyspnea relief and less WRF. Early treatment with tolvaptan 











Volume overload and subsequent congestion are the primary causes and treatment targets for acute heart failure 
(AHF)[1,2]. Diuretics have therefore been the mainstay of treatment of patients with AHF[3]. Recent studies 
however have suggested that there are patients with AHF who may be refractory to conventional diuretic 
therapy[4,5]. This poor diuretic response is a strong and independent predictor of unfavorable prognosis[6], and 
no therapy has yet been proven to benefit patients with a poor diuretic response. 
Tolvaptan is an oral, non-peptide, selective vasopressin-2 receptor antagonist, and prevents the activation of the 
aquaporin system and impairs the ability of the kidney to reabsorb water; as a result, free water excretion is 
increased. In the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, 
tolvaptan showed a favorable short-term effect but neutral long-term effect in AHF patients[7]. However, in this 
trial AHF patients were enrolled relatively late after presentation as a consequence of inclusion criteria (< 48 hours 
from hospitalization). Recent AHF studies have showed “time to treatment” is a factor associated with drug efficacy 
and patient prognosis[8,9] and the latest European Society of Cardiology heart failure guideline emphasizes the 
importance of treating AHF patients as quickly as possible[10]. Therefore, treatment with tolvaptan in the very 
early phase worth evaluating. Moreover, no study has evaluated diuretic response in Asian AHF patients. In the 
AQUAMARINE study (a randomized study evaluated efficacy of tolvaptan in patients with AHF and renal 
dysfunction), all patients were randomized within 6 hours from hospitalization. Consequently, median time from 
first presentation to randomization was 2.1 hour. In this study, we aimed to evaluate the effect of early treatment 




This is a retrospective secondary analysis of the AQUAMARINE study. The study design and primary results of 
AQUAMARINE have been described elsewhere[11,12]. In brief, 217 patients with AHF and renal dysfunction 
(estimated glomerular filtration rate, 15–60 mL/min/1.73m2) were randomized within 6 hours from hospitalization 
into two groups, either tolvaptan treatment or conventional treatment, to evaluate the efficacy of early treatment 
with tolvaptan. Fifty-three patients (48.6%) in the tolvaptan group received tolvaptan for more than 2 days, and no 
patient who was initially allocated to conventional group crossed over to tolvaptan during the first 48 hours. The 
protocol of the study was approved by the ethics committees of all participating centers, and written informed 




In the AQUAMARINE study, data regarding blood pressure, heart rate, and improvement in dyspnea from baseline 









the patient-reported seven-point Likert scale. Within 48 h, the amount of furosemide-equivalent loop diuretics, 
change in body weight from baseline, and urine output were noted down. Worsening renal function was defined 
as an increase of ≥0.3 mg/dL in the serum creatinine from the baseline at various pre-specified time points (6, 12, 
24, and 48 hours from randomization). The incidence of the combined endpoints for all-cause mortality and re-
hospitalization for heart failure within 90 days was also evaluated. 
 
Diuretic response 
We defined diuretic response as the change in body weight (kg) from baseline to 48 hours per 40 mg intravenous 
furosemide administration. Oral furosemide was converted to half the dose of intravenous furosemide. The doses 
of oral loop diuretics that were considered equivalent to 40 mg intravenous furosemide were 10 mg torasemide 
and 60 mg azosemide[13,14]. We also performed analyses by using net fluid loss within 48 hours as a measure of 
diuretic response. Diuretic response was measured according to body weight change in 189 cases after excluding 
28 cases due to missing data on the total diuretic dose (n = 3) and body weight change (n = 25). Data on diuretic 
response based on net fluid loss were achieved in 171 cases and missing in 46 cases due to unavailability of 
information on water intake in 45 cases and on furosemide dose in 3 cases.  
 
Statistical analysis 
Data were expressed as mean ± standard deviation for normally distributed variables and as median with 
interquartile range (IQR) for non-normally distributed data. Categorical data were expressed as numbers and 
percentages. The relationships between baseline characteristics, outcomes and tertiles of diuretic response were 
compared by one-way analysis of variance, Kruskal–Wallis test, or χ2 test, as appropriate. Correlation analysis was 
performed using Spearman's rho. When necessary, variables were transformed for further analyses. Stepwise 
multiple linear regression analysis was performed using backward elimination method after including all variables 
with P values below 0.10 in the univariate analysis. Statistical analyses were performed using R version 3.1.2. 
 
Results 
In the AQUAMARINE study, 220 patients were originally enrolled, of which 217 were analyzed because one patient 
in the tolvaptan group and one patient in the conventional group withdrew their consent and data were missing 
for one patient in the tolvaptan group. The baseline characteristics of randomized patients were shown 
elsewhere[12]. The median age of the patients was 75 years (interquartile range [IQR], 68 – 81 years), and 64.9% 
was male. The median left ventricular ejection fraction was 44.5%, and 82 (37.8%) patients had a left ventricular 
ejection fraction ≥ 50%. Mean baseline eGFR was 40.5 mL/min/1.73 m2, and 57 (26.3%) patients had an eGFR < 30 
mL/min/1.73 m2. Time from first-medical record input to randomization was obtained in 210 (96.8%) patients, and 
it was 2.9 hours in mean, and 2.1 hours in median. Time from patient appearance to randomization and the place 










During the first 48 hours from study enrollment, the median administered amount of furosemide-equivalent 
diuretic dose was 100 mg (IQR, 62.5–160 mg), median total body weight change was −2.30 kg (IQR, −3.50 to −1.18 
kg), and median net fluid loss was 3973.0 mL (IQR, 2566.3–5410.0 mL). The median values for the measures of 
diuretic response were −0.83 (IQR, −1.50 to −0.40) kg/40mg body weight and 1582.8 (IQR, 895–2478.3) mL/40mg 
net fluid loss. The baseline characteristics of the study population according to diuretic response tertiles are shown 
in Table 1. Using baseline characteristics, poor diuretic response based on change in body weight, was associated 
with less edematous status, less history of hypertension, and more hyponatremia. These associations were retained 
for diuretic response based on net fluid loss. In correlation analysis, change in body weight and net fluid loss 











Table 1. Baseline characteristics and relationship among tertiles of diuretic response 
Diuretic response (per 40mg 
furosemide-equivalent) [min-max] 
Diuretic response with body weight changes  
(kg/40mg furosemide) 
 


















[-10.6 – -1.20] 
-0.80 
[-1.20 – -0.50] 
-0.21 








[98.2 – 1577.1] 
Age 72±8 72±12 74±9 0.456  73±8 73±9 71±11 0.498 
Male (%) 46 (69.7) 42 (68.9) 37 (59.7) 0.421  37 (64.9) 41 (71.9) 35 (61.4) 0.482 
Body weight at baseline  63.0 (56.0-69.7) 60.0 (51.0-68.7) 60.1 (49.9-69.5) 0.409  63.0 (55.9-68.3) 61.8 (55.0-71.4) 64.1 (52.6-70.3) 0.975 
SBP (mmHg) 141±26 139±31 137±25 0.767  144±24 140±29 135±26 0.158 
DBP (mmHg) 83±19 78±22 77±19 0.188  84±18 78±18 78±18 0.113 
HR (bpm) 96±30 89±25 90±24 0.213  94±28 92±24 91±25 0.808 
Edema at baseline* (%)    0.074     0.376 
None 6 (9.1) 8 (13.1) 11 (18.0)   5 (8.8) 8 (14.0) 7 (12.5)  
Mild 15 (22.7) 25 (41.0) 23 (37.7)   15 (26.3) 13 (22.8) 21 (37.5)  
Moderate 23 (34.8) 16 (26.2) 18 (29.5)   19 (33.3) 24 (42.1) 18 (32.1)  
Severe 22 (33.3) 12 (19.7) 9 (14.8)   18 (31.6) 12 (21.1) 10 (17.9)  
Edema moderate/severe at 
baseline (%) 
45 (68.2) 28 (45.9) 27 (44.3) 0.01  37 (64.9) 36 (63.2) 28 (50) 0.212 









Pulmonary congestion at baseline 
(%) 
64 (97.0) 53 (86.9) 60 (96.8) 0.031  55 (96.5) 50 (87.7) 55 (96.5) 0.088 
NYHA III/IV (%) 48 (72.7) 36 (59.0) 39 (62.9) 0.245  42 (73.7) 39 (68.4) 42 (73.7) 0.771 
Ischemic etiology (%) 15 (22.7) 13 (21.3) 20 (32.3) 0.313  16 (28.1) 13 (22.8) 15 (26.3) 0.807 
LVEF (%) 43.3±17.5 48.7±16.1 47.7±17.3 0.161  46.2±19.1 43.7±17.1 47.8±15.9 0.443 
Medical history (%)          
HF admission 26 (39.4) 26 (42.6) 32 (51.6) 0.358  28 (49.1) 21 (36.8) 28 (49.1) 0.314 
Hypertension 56 (84.8) 41 (67.2) 50 (80.6) 0.046  52 (91.2) 35 (62.5) 43 (75.4) 0.001 
Diabetes 29 (43.9) 23 (37.7) 30 (48.4) 0.486  27 (47.4) 24 (42.1) 24 (42.1) 0.808 
Dyslipidemia 33 (50.0) 19 (31.1) 29 (46.8) 0.116  28 (49.1) 24 (42.1) 19 (33.3) 0.288 
Atrial fibrillation 38 (57.6) 31 (50.8) 32 (51.6) 0.596  30 (52.6) 31 (54.4) 32 (56.1) 0.705 
Smoking (Current or Ex) 43 (65.2) 38 (63.3) 33 (55.0) 0.467  34 (60.7) 38 (67.9) 31 (58.5) 0.57 
Drugs at admission (%)          
ACE-I 6 (9.1) 7 (11.5) 1 (1.6) 0.092  6 (10.5) 4 (7.0) 4 (7.0) 0.733 
ARB 19 (28.8) 16 (26.2) 27 (43.5) 0.085  18 (31.6) 13 (22.8) 20 (35.1) 0.336 
Beta blocker 25 (37.9) 21 (34.4) 25 (40.3) 0.795  21 (36.8) 19 (33.3) 27 (47.4) 0.279 
Aldosterone antagonist 14 (21.2) 9 (14.8) 18 (29.0) 0.157  11 (19.3) 11 (19.3) 8 (14.0) 0.695 
Digoxin 4 (6.1) 3 (4.9) 4 (6.5) 0.931  4 (7.0) 3 (5.3) 3 (5.3) 0.899 
Diuretics  27 (40.9) 23 (37.7) 28 (45.2) 0.701  20 (35.1) 25 (43.9) 24 (42.1) 0.6 
Furosemide equivalent dose among 
users (mg) 
40 (5-80) 40 (10-200) 40 (10-120) 0.356  40 (10-80) 20 (10-120) 40 (5-200) 0.575 









IV therapy within 48 hours (%)          
Carperitide 25 (37.9) 23 (37.7) 19 (30.6) 0.628  25 (43.9) 24 (42.1) 12 (21.1) 0.018 
Dopamine 1 (1.5) 0 (0.0) 2 (3.2) 0.359  0 (0.0) 2 (3.5) 0 (0.0) 0.132 
Dobutamine 5 (7.6) 5 (8.2) 9 (14.5) 0.359  3 (5.3) 7 (12.3) 8 (14.0) 0.271 
Nitrate 16 (24.2) 10 (16.4) 9 (14.5) 0.321  16 (28.1) 8 (14.0) 11 (19.3) 0.172 
Vasodilator  17 (25.8) 10 (16.4) 11 (17.7) 0.359  16 (28.1) 9 (15.8) 13 (22.8) 0.286 
Heparin 34 (51.5) 19 (31.1) 25 (40.3) 0.065  32 (56.1) 17 (29.8) 24 (42.1) 0.018 
Lab data at baseline          
Creatinine 1.5±0.6 1.3±0.5 1.5±0.5 0.148  1.4±0.5 1.4±0.5 1.5±0.7 0.728 
eGFR 38.3±13.9 43.5±12.2 38.9±13.4 0.056  39.1±13.6 42.0±13.2 40.2±14.2 0.503 
BUN 28 (20-35) 26 (19-35) 28 (20-37) 0.891  24 (19-32) 28 (18-35) 28 (22-35) 0.466 
Sodium 141±4 141±3 139±4 0.017  141±4 140±4 139±5 0.149 
















Dose of diuretics use within 48 
hours (mg) 
60 (23-100) 100 (80-140) 140 (100-200) <0.001  60 (20-80) 100 (80-140) 160 (110-220) <0.001 
Urine volume within 48 hours (mL) 6584.1±3559.0 6192.2±2399.2 4500.3±1679.1 <0.001  7319.9±3599.0 5974.9±1877.2 4399.8±1906.5 <0.001 
Water intake within 48 hours (mL) 1867.3±1434.1 1685.3±986.4 1446.0±933.4 0.183  1902.5±1456.2 1497.4±739.4 1488.3±1054.2 0.082 









Body weight changes within 48 
hours (kg) 
-3.8 (-5.3--2.6) -2.4 (-2.9--1.6) -0.9 (-1.5-0.0) <0.001  -3.0 (-4.7--2.0) -2.4 (-3.3--1.3) -1.4 (-2.5--0.8) <0.001 










To identify predictors of diuretic response, univariable (Supplemental Table 1) and multivariable linear regression 
analysis (Table 2) for both parameters were performed. The only independent predictors of a good diuretic 
response for both criteria were tolvaptan use and a higher diastolic blood pressure. There was no interaction 
between baseline diuretics and tolvaptan on diuretic response for both BW definition (P value for interaction = 
0.816) and net fluid loss definition (P value for interaction = 0.642). Likewise, no significant interaction was 
observed between baseline sodium level, renal function, and impact of tolvaptan treatment on diuretic response 
(all P value for interaction > 0.20). For both diuretic response definitions, no interaction was found on the effect of 
tolvaptan on diuretic response between patients who were treated with and without carperitide (P for interaction 
= 0.137 with body weight definition and 0.707 with net fluid loss definition). 
 
Table 2. Multivariable linear regression analysis of diuretic response  
Variable Standardized Beta t P value 
Diuretic response with body weight changes (kg/40mg furosemide) 
Adjusted R2=0.214 
Tolvaptan treatment -0.339 -5.246 <0.001 
Heparin IV -0.241 -3.707 <0.001 
DBP -0.149 -2.279 0.024 
Edema (moderate/severe) -0.137 -2.088 0.011 
Diuretic response with Net fluid loss (mL/40mg furosemide) 
Adjusted R2=0.176 
Tolvaptan treatment 0.387 5.495 <0.001 
DBP 0.199 2.854 0.005 
 
 
Patients with a poor diuretic response were less likely to have an improvement in dyspnea relief within 48 hours 
from randomization, as defined by moderate or marked improvement from baseline according to the seven-point 
Likert scale (Table 3). A poor diuretic response was also significantly associated with more WRF (Table 3). A worse 










Table 3. Outcomes of the tertiles of diuretic response 
Diuretic response (per 40mg furosemide-
equivalent) [min-max] 
Diuretic response with body weight changes (kg/40mg 
furosemide) 
  



























Dyspnea relief (moderately or markedly)          
6 hours 15 (22.7) 10 (16.4) 8 (12.9) 0.331  14 (24.6) 8 (14.0) 8 (14.0) 0.223 
12 hours 25 (39.1) 20 (32.8) 10 (16.4) 0.017  24 (42.9) 18 (31.6) 11 (19.3) 0.026 
24 hours 35 (53.0) 31 (51.7) 12 (19.4) <0.001  33 (57.9) 29 (50.9) 12 (21.1) <0.001 
48 hours 52 (80.0) 44 (72.1) 21 (34.4) <0.001  47 (83.9) 44 (78.6) 18 (31.6) <0.001 
WRF (Cre increase ≥0.3mg/dL from baseline) 
(%) 
11 (16.7) 13 (21.3) 22 (35.5) 0.037  8 (14.0) 13 (22.8) 22 (38.6) 0.009 









Prognosis within 90 days (%)          
Death 1 (1.5) 2 (3.3) 4 (6.5) 0.335  1 (1.8) 3 (5.3) 3 (5.3) 0.551 









Figure 1 shows the diuretic response according to randomization group, i.e. with and without tolvaptan treatment. 
Compared to patients who were not treated with tolvaptan, those who were treated with tolvaptan showed a 
significantly better diuretic response based on assessment by both body weight change [−1.16 (IQR, −3.00 to −0.57) 
kg/40 mg vs. −0.51 (IQR, −1.13 to −0.20) kg/40 mg; P < 0.001] and net fluid loss [2125.0 (IQR, 1370.0 to 3856.3) 
mL/40 mg vs. 1296.3 (IQR, 725.2 to 1726.5) mL/40 mg; P < 0.001]. 
 
Figure 1. Diuretic response in patients with acute heart failure according to treatment with tolvaptan 
Measurements compared were (A) change in body weight and (B) net fluid loss 
 
Discussion 
In patients with AHF and renal dysfunction, very early treatment with tolvaptan was independently associated with 
better diuretic response. AHF patients with poor diuretic response had less dyspnea relief and more frequently 
experienced worsening renal function.  
 
Diuretic response in AHF 
In spite of the lack of a universal definition, poor response to diuretic therapy has been shown to be one of the 
most powerful prognostic predictors in patients with heart failure[4,13,15,16]. Initial studies used diuretic dose to 
define diuretic response, i.e., patients with persistent heart failure despite treatment with a certain dose of 









diuretics and hereby obviously ignored response to the diuretics and therefore assumed equal effectiveness. 
Recently, a novel definition of diuretic response based on urine/body weight response to a certain amount of 
diuretics was proposed[6]. In all studies that evaluated its prognostic potential, diuretic response consistently 
showed significant prognostic ability in patients with AHF when this modified definition was used[4,5,18,19].  
There has been no consensus on the parameter used to measure diuretic response to 40 mg furosemide or its 
equivalent, although recent studies have used either change in body weight, net fluid loss, or total urinary output. 
In the present study, we showed relatively poor correlation between the two measures of diuretic response. This 
result was in line with that of the DOSE trial and ASCEND-HF, which demonstrated a poor agreement between net 
fluid loss and weight loss[5,20]. It is clear that we need better measures of diuretic response to encompass 
natriuretic response, change in volume distribution, and change in hemodynamic status. However, our consistent 
results on the improvement of diuretic response, by two different parameters, with tolvaptan supported our 
hypothesis. 
 
According to this novel definition, the median diuretic response was −0.51 kg/40 mg/48 hours furosemide in the 
conventional group in our study. This was greater than approximately 0.4 kg/40 mg of furosemide-equivalent 
diuretic response in the patients of the ASCEND-HF (weight change from admission to 48 hours), RELAX-AHF 
(weight change from day1 to 5), and PROTECT (weight change from day1 to 4) studies[4,5,18]. This better diuretic 
response in this AQUAMARINE cohort did not match our expectations because our study included only AHF patients 
with renal dysfunction on admission and earlier studies suggest that renal dysfunction predisposes to worse 
diuretic response[4,5,18]. There are several conceivable speculations for this unexpected result. First, lower doses 
of loop diuretic were given in AQUAMARINE, compared to other studies and the additional effect of a drug usually 
decreases at higher doses.  Second, although baseline creatinine values were higher in the AQUAMARINE cohort 
than in the ASCEND-HF cohort, levels of baseline blood urea nitrogen were not substantially different between 
these two studies. Given that blood urea nitrogen, but not creatinine, has been suggested by previous studies as 
the most powerful determinant of diuretic response[4,21], this may be one of the reasons for discrepancy in our 
study. Third, median time till randomization from patient arrival was 2.1 hours and 41.4% of all AQUAMARINE 
cohort was randomized before admission at the emergency department or clinic. This is surprisingly short given 
that mean time from admission to randomization was 15.5 hours in ASCEND-HF and 7.9 hours in RELAX-AHF[22]. 
This means AQUAMARINE randomized AHF patients much earlier, and we could therefore evaluate diuretic 
response in the very early phase which was not possible with previous diuretic response studies in AHF cohorts. 
This difference in the time window might be associated with the unexpected good diuretic response in our study 
cohort. Finally, our results lead to hypothesis that there may be a racial difference in diuretic response. All of the 
studies regarding diuretic response so far predominantly enrolled Western AHF patients and little is currently 
known about diuretic response in Asian AHF patients. This hypothesis is supported by the observation that the 
amount of intravenous loop diuretics used in the acute phase was very low (around or less than 100mg/48 hours) 
in Japanese AHF patients compared to Western patients[12,23]. Therefore, influence of racial and/or genetic 










For both diuretic response parameters, high blood pressure was associated with a good diuretic response. These 
findings were in accordance with the results of previous studies. In the PROTECT, RELAX-AHF, and ASCEND-HF 
cohorts, low diastolic blood pressure was an independent predictor of poor diuretic response[4,5,18]. Interestingly, 
intravenous unfractionated heparin was associated with good diuretic response measured with body weight. We 
have no clear explanation for this finding; however, hyperkalemia is known to be a rare but possible complication 
of heparin therapy[24], and hypokalemia was suggested as an independent predictor of poor diuretic response in 
PROTECT. Moreover, there is a case report that suggests a direct effect of heparin on diuresis in patients with 
AHF[25]. The association between intravenous heparin and diuretic response needs to be precisely elucidated in 
the future studies.     
 
Poor diuretic response was significantly associated with a high incidence of worsening renal function and low rate 
of improvement in dyspnea at almost all time points. These results are in line with the findings of previous 
studies[4,18]; however, it should be acknowledged that the number of events were very small and this study was 
obviously underpowered to evaluate prognostic significance of diuretic response.  
 
Effect of tolvaptan on diuretic response 
Although some interventions to treat AHF patients with diuretic resistance have been investigated, there has been 
no proven therapy to improve diuretic resistance in this high risk population. In the ROSE-AHF study, neither low-
dose nesiritide nor low-dose dopamine on top of standard of therapy was associated with a greater reduction in 
body weight within 72 hours[26]. Given that the total amount of furosemide-equivalent diuretic used within 72 
hours was not significantly different, neither low-dose dopamine nor low-dose nesiritide was suggested to improve 
diuretic response. Likewise, in ASCEND-HF, nesiritide did not improve diuretic response[5]. In RELAX-AHF, serelaxin 
did not show a significant improvement in diuretic response of patients with AHF despite its potentially favorable 
effects on prognosis [18,27,28]. Rolofylline, an adenosine A1-receptor antagonist, on the other hand did improve 
diuretic response[4]. However, its clinical use was hampered by a neutral effect on prognosis and the concern for 
neurological adverse events. Ultrafiltration might be a promising decongestive strategy[29]; however, it has not 
been studied specifically in patients with a poor diuretic response.  
 
In the present study, we showed that very early treatment with tolvaptan could improve diuretic response in AHF 
patients with renal impairment. The pathophysiological background of this favorable effect of tolvaptan on diuretic 
response remains to be elucidated; however, it may be attributed to certain differences in the mechanisms of action 
between loop diuretics and tolvaptan. First, time-dependent diuretic resistance was observed with loop diuretics. 
In patients who have been treated with diuretics for a long time, effectiveness is blunted gradually with time[30]. 
Second, loop diuretics have to be bound to plasma albumin and delivered to the proximal tubules in order to exert 
their effects. Therefore, hypoalbuminemia, which is common in patients with AHF, could contribute to poor diuretic 









for them to act[33]. This transporter could be inhibited by endogenous organic anions[34]. However, compared 
with furosemide, tolvaptan has a different mechanism of action, i.e., inhibiting the activation of vasopressin-2 
receptor by arginine–vasopressin and subsequent insertion of aquaporin-2 channels in the collecting tubules. This 
might be one of the reasons for the improvement in diuretic response in renal-impaired patients with AHF after 
intake of tolvaptan. 
Contrary to our result, recent sub-analysis from EVEREST showed a lack of significant difference in prescription rate 
of tolvaptan between good/bad diuretic response groups[35]. There are some differences in patient backgrounds 
between EVEREST and AQUAMARINE that possibly explain this discordance (e.g. racial difference, baseline renal 
function). However, the most conceivable explanation for this discrepancy is time to treatment. In EVEREST, time 
from hospitalization to dyspnea assessment (the next calendar day after the first drug administration) was more 
than 36 hours in 47.7%, and more than 60 hours in 20.2%[36]. In AQUAMARINE about 40% of all patients were 
randomized before admission to the hospital ward and this early capture of AHF patients may lead to short time to 
randomization and better diuretic response. The association between time to therapy and diuretic response in AHF 
patient needs to be addressed in future studies.  
 
Tolvaptan is expected to cause aquaresis but not natriuresis. As sodium retention plays a pivotal role in 
pathophysiology of AHF, aquaresis may have a different impact on prognosis from natriuresis in AHF patients. 
Although the pathophysiological background of the association between diuretic response and prognosis has yet 
to be elucidated, early successful decongestion and subsequent symptom relief are plausible mechanisms. Given 
that several studies, including AQUAMARINE, have consistently showed urine output with tolvaptan (i.e. aquaresis) 
could also lead to decongestion and subsequent symptom relief, improvement of diuretic response with early 
treatment with tolvaptan in AHF patients potentially improves outcome. From this perspective, EVEREST might not 
be suitable to evaluate this hypothesis as tolvaptan was used relatively late and did not improve diuretic response. 
As we showed improvement in diuretic response with very early treatment with tolvaptan for the first time, future 
studies on early use of tolvaptan for patients with AHF having poor diuretic response are warranted.  
 
Our study had several limitations; primarily, its open-label design, which could have influenced some subjective 
prognostic variables, including relief of dyspnea. This study focused on short-term responses and did not have 
sufficient power to detect long term differences in WRF. We could not address the association between diuretic 
response and prognosis because of very little number of events. As we recruited and randomized patients very 
early in our study, some non-AHF patients might have been included. However, all patients went through careful 
clinical history taking, physical examination, chest X-ray and analysis of natriuretic. Only after confirmation that 
patients met the criteria as stated in the protocol, they were randomized and received the study drug. In addition, 
we performed sensitivity analyses comparing the effects of tolvaptan in patients with a BNP between 100 – 350 
pg/ml and above 350 pg/mL We found no interaction in the effect of tolvaptan on diuretic response in patients 
with higher versus lower BNP levels at admission (P value for interaction = 0.183). No standardized diuretic regimen 









between diuretic response and dyspnea relief should be interpreted carefully because baseline severity of dyspnea 
was not evaluated and difference in baseline dyspnea severity between good and poor diuretic response group 
might affect difference in degree of dyspnea relief. 
The most powerful limitation of this study which should be acknowledged is that this is a post-hoc and non-pre-
specified analysis. Moreover, several analyses were performed without adjusting for multiple testing. Given these 
points, our study result should be interpreted as an exploratory analysis and hypothesis generating. 
 
Conclusions 
Very early treatment with tolvaptan improved diuretic response in patients with a hospital admission for AHF. 
Future research focusing on the prognostic implication of improving diuretic response with early treatment with 
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Supplemental Table 1. Univariable linear regression analysis for diuretic response 
Variables 
Diuretic response with body weight 
changes   
Diuretic response with Net fluid loss 
(kg/40mg furosemide) (mL/40mg furosemide) 
Standardized beta t P value   Standardized beta t P value 
Age (years) 0.04 0.548 0.585  -0.009 -0.121 0.904 
Male (%) -0.085 -1.169 0.244   0.003 0.045 0.964 
SBP (mmHg) -0.157 -2.177 0.031  0.156 2.047 0.042 
DBP (mmHg) -0.196 -2.73 0.007   0.152 1.982 0.049 
Heart rate (bpm) -0.12 -1.654 0.099  0.051 0.656 0.513 
Left ventricular ejection 
fraction (%) 
0.125 1.710 0.089   -0.055 -0.71 0.478 
NYHA III/IV (%) -0.046 -0.629 0.531  -0.001 -0.011 0.991 
Tolvaptan treatment  -0.349 -5.092 <0.001   0.404 5.711 <0.001 
Medical History (%)        
HF admission 0.079 1.086 0.279   0.016 0.2 0.841 
Hypertension -0.097 -1.333 0.184  0.100 1.299 0.196 
Diabetes -0.032 -0.433 0.666   0.001 0.009 0.993 
Dyslipidemia  0.009 0.126 0.9  0.024 0.309 0.757 
Atrial fibrillation  -0.025 -0.335 0.738   -0.018 -0.229 0.819 
Smoking (Current or Ex) -0.135 -1.843 0.067  0.042 0.534 0.594 
Drug at admission (%)         
Furosemide equivalent dose 
(mg) 
0.065 0.891 0.374  -0.139 -1.813 0.072 
ACE -0.042 -0.573 0.567   0.024 0.298 0.766 
ARB 0.083 1.141 0.255  -0.055 -0.714 0.476 
Beta blocker -0.002 -0.025 0.98   -0.07 -0.913 0.362 
Aldosterone antagonist 0.073 0.996 0.321  0.044 0.566 0.572 
Digoxin 0.025 0.338 0.735   -0.018 -0.231 0.817 
Time to Randomization (hour) -0.113 -1.532 0.127  0.015 0.192 0.848 
IV therapy w/i 48h (%)         
Carperitide -0.146 -2.02 0.045  0.195 2.574 0.011 
Nitrate -0.217 -3.041 0.003   0.137 1.787 0.076 









Vasodilator -0.195 -2.715 0.007   0.103 1.335 0.184 
Nicorandil 0.016 0.214 0.831  -0.089 -1.149 0.252 
Heparin -0.233 -3.275 0.001   0.109 1.428 0.155 
Dopamin 0.026 0.357 0.722  0.003 0.045 0.964 
Dobutamin 0.117 1.619 0.107   -0.129 -1.683 0.094 
Lab data        
Creatinine (mg/dL) -0.112 -1.542 0.125   -0.031 -0.408 0.684 
eGFR (mL/min/1.73m2) 0.072 0.988 0.324  -0.032 -0.417 0.677 
BUN (mg/dL) -0.007 -0.101 0.919   -0.161 -2.107 0.037 
Na (mEq/L) -0.119 -1.643 0.102  0.164 2.154 0.033 
K (mEq/L) -0.066 -0.909 0.365   0.011 0.14 0.889 
BNP (pg/mL) -0.108 -1.479 0.141  -0.045 -0.584 0.56 
Body weight at admission (Kg) -0.037 -0.505 0.615   -0.002 -0.027 0.979 
Edema (moderate/severe) -0.191 -2.647 0.009  0.177 2.317 0.022 
Orthopnea -0.105 -1.448 0.149   0.046 0.601 0.549 
Pulmonary Congestion -0.048 -0.656 0.513  0.043 0.553 0.581 
Water intake -0.069 -0.854 0.395   0.169 2.21 0.029 
* Time-to-randomization was missing in 3 patients 
 
 
Supplemental Figure 1. Place of initial presentation, randomization timing, and time from presentation to 












Supplemental Figure 2. Scatter plot between body weight change and net fluid loss with fit line and its 95% 
confidence interval (shaded area) 
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Acute heart failure (AHF) is a life-threatening disease requiring urgent treatment, including a recommendation for 
immediate initiation of loop diuretics. 
OBJECTIVES We prospectively evaluated the association between time-to-diuretic treatment and clinical outcome.  
 
Methods 
REALITY-AHF (Registry Focused on Very Early Presentation and Treatment in Emergency Department of Acute Heart 
Failure) was a prospective, multicenter, observational cohort study that primarily aimed to assess the association 
between time to loop diuretic treatment and clinical outcome in patients with AHF admitted through the 
emergency department (ED). Door-to-furosemide (D2F) time was defined as the time from patient arrival at the ED 
to the first intravenous furosemide injection. Patients with a D2F time <60 min were pre-defined as the early 
treatment group. Primary outcome was all-cause in-hospital mortality.  
 
Results  
Among 1,291 AHF patients treated with intravenous furosemide within 24 h of ED arrival, the median D2F time was 
90 min (interquartile range: 36 to 186 min), and 481 patients (37.3%) were categorized as the early treatment group. 
These patients were more likely to arrive by ambulance and had more signs of congestion compared to the non-
early treatment group. In-hospital mortality was significantly lower in the early treatment group (2.3% vs 6.0% in 
the non-early treatment group; p = 0.002). In multivariate analysis, earlier treatment remained significantly 
associated with lower in-hospital mortality (odds ratio: 0.39; 95% confidence interval: 0.20 to 0.76; p = 0.006).      
 
Conclusions  
In this prospective multicenter, observational cohort study of patients presenting at the ED for AHF, early treatment 
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AHF = acute heart failure 
BNP = B-type natriuretic peptide 
D2F = door-to-furosemide 
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Acute heart failure (AHF) is a life-threatening disease that remains an important public health issue, with high 
morbidity, mortality, and economic burden. While a paradigm shift has occurred regarding treatment of chronic 
systolic heart failure (HF), the management of AHF has not changed for several decades, and most clinical studies 
investigating several drugs targeting this population have failed to demonstrate a favorable prognostic impact (1). 
The emergency department (ED) is a major stage for hospitalized patients with AHF. In the United States, almost 1 
million ED visits for AHF occur per year, with ≥80% of patients admitted (2,3). The importance of the ED phase in 
managing AHF has become increasingly apparent as recent post hoc studies have highlighted the fact that while 
patient characteristics are important, the efficacy of any intervention/treatment may be time dependent (4-6). 
Therefore, recent HF guidelines and recommendations emphasized the importance of immediate diagnosis and 
treatment of patients presenting with AHF (7,8). However, this concept has only been evaluated using retrospective 
data. REALITY-AHF (Registry Focused on Very Early Presentation and Treatment in Emergency Department of Acute 
Heart Failure), was a prospective multicenter study to evaluate the association between time to treatment and 
clinical outcome in AHF patients presenting at the ED.  
 
METHODS  
The main objective of REALITY-AHF was to determine the prognostic impact of time to treatments for AHF 
performed in the acute phase. All consecutive patients with AHF hospitalized through the ED at participating 
hospitals were enrolled upon the initial hospital admission. Only the first hospitalization during the study period 
was registered. Patients were included if they were age ≥20 years old and diagnosed with AHF in the ED within 3 h 
of their first evaluation by caregivers. The AHF diagnosis was made based on Framingham criteria (9). Exclusion 
criteria were: 1) treatment with an intravenous (IV) drug prior to ED arrival; 2) previous heart transplantation; 3) 
on either chronic peritoneal dialysis or hemodialysis; 4) acute myocarditis; and 5) acute coronary syndrome 
requiring emergent or urgent revascularization. Patients with missing B-type natriuretic peptide (BNP) or N-
terminal-proBNP (NT-proBNP) data, and patients with a BNP level <100 pg/ml or NT-proBNP level <300 pg/ml at 
baseline were also excluded. Enrollment was performed from August 2014 to December 2015. Among the 20 
participating hospitals, 9 were university hospitals and 11 were nonuniversity teaching hospitals. 
Since all patients were enrolled at the ED, the time of ED arrival was recorded, and data were collected for up to 
48 h from the time of ED arrival. Drug and doses of all IV treatments were recorded. Additionally, the time from 
arrival to the “first IV furosemide” administration was recorded for all patients as it was the primary pre-specified 
variable of interest. Oral medication taken within 48 h was also recorded for all HF medications, including the 
amount of diuretics. Baseline physical findings and blood samples were taken and evaluated in the ED for all 
patients. Echocardiography was performed at the ED and subsequent steady-state phases. Left ventricular ejection 
fraction was assessed by echocardiography at the ED and categorized into 3 groups: <35%; 35% to 50%; and >50%.  
Importantly, the nature of this study did not require participants to use any particular drug or treatment strategy. 
The mission of the registry was to capture patients with AHF immediately after arrival to the ED and for the study 









at the ED may cause a delay in the ED management timeline, and subsequently biasing the results, we utilized an 
opt-out method for participant recruitment. All participants were notified regarding their participation in the study 
and it was explained that they were free to opt out of participation at any time. Our study complied with the 
Declaration of Helsinki and Japanese Ethical Guideline for Medical and Health Research involving Human Subjects. 
The study protocol was approved by the ethics committee of each participating hospital. Study information 
including objectives, inclusion and exclusion criteria, and the names of participating hospitals were published in 
the publically available University Hospital Information Network (UMIN-CTR, unique identifier: UMIN000014105) 
before the first patient was enrolled. 
DOOR-TO-FUROSEMIDE TIME. Patients who were treated with IV furosemide within 48 h of ED arrival were 
included in the present study. The exact time of the first IV furosemide administration was recorded; the time from 
ED arrival to the administration of the first IV furosemide was defined as the door-to-furosemide (D2F) time. 
Patients with missing D2F time were excluded. To distinguish IV diuretics used for treating the initial AHF symptoms 
from treatment for deteriorated HF symptoms caused after the initial phase, we included only patients with a D2F 
time <24 h. In accordance with published recommendations of the European Society of Cardiology regarding early 
and prehospital management of AHF, we defined early and nonearly treatment groups using the D2F time with a 
cut-off of 60 min (8). The primary endpoint was all-cause in-hospital mortality. 
 
STATISTICAL ANALYSIS  
Data are expressed as mean ± SD for normally distributed variables and as median with interquartile range (IQR) 
for non-normally distributed data. Categorical data are expressed as numbers and percentages. When necessary, 
variables were transformed for further analyses. Group differences were evaluated using Student t tests or Mann-
Whitney U tests for continuous variables and chi-square or Fisher exact tests for categorical variables. The Get With 
the Guidelines-Heart Failure (GWTG-HF) risk score was calculated for each patient as previously described (10). The 
GWTG-HF risk score is based on race, age, systolic blood pressure, heart rate, blood urea nitrogen, sodium levels, 
and the presence of chronic obstructive pulmonary disease. The discrimination and calibration of this risk score 
have been well validated in Japanese patients with AHF (11); therefore, the GWTG-HF score was used as an 
adjustment variable in a multivariable prognostic model. Additionally, the patients were stratified according to 
GWTG-HF risk score quartiles and quartile groups were evaluated for differences in in-hospital mortality to examine 
the relationship between GWTG-HF scores at baseline and the prognostic impact of early treatment. 
Univariable and multivariable logistic regression analyses were performed to evaluate the association between 
early treatment and in-hospital prognosis. Furthermore, generalized estimating equation (GEE) models were used 
to account for intrainstitutional correlations among patients. The presence of a nonlinear association between D2F 
time and in-hospital mortality was evaluated using a linear regression model with restricted cubic splines of 3, 4, 
and 5 knots. The goodness-of-fit was compared between models using an analysis of variance test.  
To control confounding as much as possible, propensity score matching was also performed as a sensitivity analysis. 
The propensity score was estimated based on a logistic model constructed with the following variables: age; sex; 









hemoglobin, aspartate aminotransferase, alanine aminotransferase, serum sodium, blood urea nitrogen, BNP, and 
glucose; history of chronic obstructive pulmonary disease; presence/absence of jugular venous distension, 
orthopnea, peripheral edema, or rales at baseline; and prescription of an angiotensin-converting enzyme inhibitor 
or loop diuretics at admission. Propensity score matching was performed for the early and nonearly treatment 
groups with one-to-one caliper matching using a caliper width equal to 20% of the SD of the logit of the calculated 
propensity score (12). To assess the performance of the matching, standardized mean differences were calculated 
for all baseline variables and a difference below 0.1 was considered negligible (i.e., the 2 groups were well balanced) 
(13). 
A two-tailed p value < 0.05 was considered statistically significant. Statistical analyses were performed using R 
version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria). 
 
RESULTS  
During the study period, 1,762 patients meeting inclusion criteria were registered in the REALITY-AHF study (Figure 
1). Eighty patients met exclusion criteria, leaving 1,682 patients; among these patients, 1,393 (82.8%) were given 
IV furosemide within 48 h of ED arrival. After excluding patients without an available D2F time or a D2F time of >24 
h, the final cohort for analysis included 1,291 patients. 
 
D2F time was non-normally distributed with a median value of 90 min (IQR: 36 to 186 min). Using a cutoff of 60 









treatment group. Baseline characteristics for the groups are shown in Table 1. Patients in the early treatment group 
were more likely to arrive by ambulance; had acute onset of symptoms, higher blood pressure, and heart rate; and 
were more likely in sinus rhythm compared to those in the nonearly treatment group. Moreover, the early 
treatment group showed more signs of congestion, including higher New York Heart Association class and physical 
symptoms compared to the nonearly treatment group. Prescription of loop diuretics and mineralocorticoid 
receptor antagonists before admission were more prevalent in the nonearly compared to the early treatment group.  
 








Treatment Group p Value 
(n = 481) (n = 810) 
Age, yrs 0 79 ± 11 78 ± 13 0.391 
Male 0 254 (53) 471 (58) 0.072 
Arrived by ambulance  0 349 (73) 428 (53) <0.001 
Symptom onset time  0   <0.001 
≤6 h  150 (31) 162 (20)  
6 h-2 days  103 (21) 179 (22)  
> 2 days  228 (47) 469 (58)  
Systolic blood pressure, mm Hg 1 (0.1) 157 ± 37 147 ± 35 <0.001 
Diastolic blood pressure, mm Hg 4 (0.3) 87 ± 26 83 ± 25 0.003 
Heart rate, beats/min 0    
Total   102 ± 29 97 ± 28 0.001 
Sinus patients  99 ± 22 93 ± 22 <0.001 
AF patients   113 ± 32 105 ± 31 0.008 
ECG rhythm 1 (0.1)   0.028 
Sinus  286 (60) 419 (52)  
AF  155 (32) 307 (38)  
Others  40 (8) 83 (10)  
LVEF at ED 1 (0.1)   0.428 
<35%  162 (37) 282 (37)  
35%-50%  144 (33) 222 (29)  
>50%  135 (30) 253 (34)  
NYHA III/IV at admission 1 (0.1) 426 (90) 632 (85) 0.012 
Medical history     









Hypertension  0 342 (71) 539 (67) 0.095 
Diabetes mellitus 0 180 (37) 294 (36) 0.720 
Coronary artery disease  0 160 (33) 240 (30) 0.191 
COPD 0 52 (11) 74 (9) 0.333 
Current or ex-smoker 0 191 (40) 305 (38) 0.478 
Physical findings at ED     
Peripheral edema  1 (0.1) 366 (76) 547 (68) 0.001 
JVD 21 (1.6) 326 (69) 444 (56) <0.001 
Orthopnea 4 (0.3) 361 (75) 453 (56) <0.001 
Pulmonary edema 0 391 (81) 586 (72) <0.001 
Rale 2 (0.2) 370 (77) 522 (65) <0.001 
Clinical profiles at ED 77 (6)   0.616 
Warm-Dry  12 (3) 28 (4)  
Warm-Wet  391 (83) 594 (80)  
Cold-Dry  54 (11) 92 (12)  
Cold-Wet  16 (3) 27 (4)  
Medication at admission     
Loop diuretics  0 204 (42) 437 (54) <0.001 
ACE-I 5 (0.4) 78 (16) 141 (18) 0.592 
ARB 4 (0.3) 159 (33) 243 (30) 0.291 
Beta-blocker 8 (0.6) 190 (40) 341 (42) 0.379 
Aldosterone blocker  1 (0.1) 86 (18) 192 (24) 0.014 
Lab data     






Hemoglobin, g/dl   0 11.5 (10.2-13.2) 11.7 (10.3-13.3) 0.512 
AST, IU/l 1 (0.1) 32 (24-49) 31 (23-46) 0.833 
ALT, IU/l 2 (0.2) 23 (14-35) 22 (14-36) 0.259 
Creatinine, mg/dl 0 1.3 ± 0.9 1.4 ± 1.0 0.240 
BUN, mg/dl 0 25 (18-33) 24 (18-35) 0.740 
Glucose, mg/dl 51 (3.9) 181 ± 82 159 ± 73 <0.001 
Sodium, mEq/l 1 (0.1) 139 ± 4 138 ± 5 0.452 









Length of hospital stay, days 0 17 (11-26_ 17 (11-26 0.457 









Values are mean ± SD, n (%), or median (interquartile range). 
ACE-I = angiotensin-converting enzyme inhibitor; ALT = aspartate aminotransferase; ARB = angiotensin II receptor 
blocker; AST = alanine aminotransferase; BNP = B-type natriuretic peptide; BUN = blood urea nitrogen; COPD = 
chronic obstructive pulmonary disease; CRP = C-reactive protein; ECG = electrocardiogram; ED = emergency 
department; GWTG-HF = Get With the Guidelines-Heart Failure; JVD = jugular venous distention; LVEF = left 
ventricular ejection fraction; NYHA = New York Heart Association; WBC = white blood cell. 
 
Significant group differences in baseline laboratory markers were only found for the white blood cell count and 
glucose level. GWTG-HF risk score showed that the risk of the early treatment group was slightly lower than the 
nonearly treatment group. In terms of other treatments performed within 48 h, there were no significant group 
differences in the percentage of patients receiving catecholamines (dopamine, norepinephrine, or dobutamine): 
16% in the early treatment group versus 15.5% in the nonearly treatment group (p = 0.812) or in the use of 
vasodilators (60.5% vs. 59.3%, respectively; p = 0.681). As more patients in the nonearly treatment group had a 
history of HF and had received treatment with furosemide before admission, we separately evaluated group 
differences in the amount of oral diuretics taken within 48 h among patients with and without a history of HF. No 
significant group differences in the amount of diuretics taken during this time period were found among those with 
(40 mg [IQR: 0 to 80 mg] vs. 40 mg [IQR: 20 to 80 mg]; p = 0.124) and without (0 mg [IQR: 0 to 30 mg] vs. 0 mg [IQR: 
0 to 40 mg]; p = 0.690) a history of HF. 
The results for the univariable and multivariable linear regression analyses predicting log-transformed D2F time 
are shown in Online Table 1 and Table 2, respectively. Arriving by ambulance and the presence of signs and 
symptoms of congestion, including orthopnea, jugular venous distension, angiotensin II receptor blocker 
prescription at admission, and a high heart rate were independently associated with a shorter D2F time. In the final 
multivariable linear regression model, none of the individual covariate variance inflation factors was greater than 
2 and the mean variance inflation factor across all covariates was 1.06. 
 
Table 2. Log-transformed Door-to-furosemide Time 
Variable B Coefficient* Standardized* Beta t Value* p Value 
Orthopnea -0.455 -0.178 -6.278 <0.001 
Arrived by ambulance -0.323 -0.128 -4.646 <0.001 
JVD -0.307 -0.121 -4.371 <0.001 
Heart rate -0.003 -0.077 -2.781 0.006 
Male 0.137 0.055 2.055 0.040 
ARB at admission -0.143 -0.054 -1.979 0.048 
*A factor with a negative coefficient is associated with an earlier administration of intravenous furosemide. 
Abbreviations as in Table 1. 
 
D2F TIME AND IN-HOSPITAL MORTALITY  
No patient was lost to follow-up for in-hospital outcome. During the index hospitalization, 11 patients (2.3%) in the 









mortality rate increased as GWTG-HF risk score increased in both groups (p for trend < 0.05 for both groups), a 
lower mortality rate in the early treatment group compared to that for the nonearly treatment group was 
consistently observed across all quartiles, with the absolute risk difference increasing as GWTG-HF risk score 
quartile rose (p for trend = 0.027) (Figure 2). Table 3 shows the results of the univariable and multivariable logistic 
regression analyses. In logistic regression models, early treatment was associated with lower in-hospital mortality 
compared to nonearly treatment, even after adjustment for the GWTG-HF risk score. In GEE models, early 
treatment was associated with lower in-hospital mortality in univariate analysis (odds ratio [OR]: 0.36; 95% 
confidence interval [CI]: 0.21 to 0.62; p < 0.001) and after adjustment for the GWTG-HF risk score (OR: 0.42; 95% 
CI: 0.24 to 0.72; p < 0.001). In multivariable analysis, no significant interaction was seen between the early 
treatment group and GWTG-HF risk score on in-hospital mortality (p for interaction = 0.916). Additionally, there 
were no significant interactions between early treatment and any of the congestion symptoms (peripheral edema, 
jugular venous distension, orthopnea, pulmonary edema, and rales), arriving with ambulance or not, and sex (p for 
interaction > 0.3 for all). The association between early treatment and in-hospital mortality did not differ 
significantly in patients with a history of HF (OR: 0.43; 95% CI: 0.19 to 1.00; p = 0.051) and without a history of HF 










Figure 2. In-hospital Mortality  
Early treatment resulted in lower mortality overall and stratified by quartiles of Get with the Guidelines-Heart 
Failure Score. 
 





Odds Ratio 95% CI p Value Odds Ratio 95% CI p Value 
Univariate 0.36 0.19-0.71 0.002  0.52 0.28-0.96 0.037 
Adjusted for GWTG-HF risk score 0.39 0.20-0.76 0.006   0.56 0.13-1.0 0.072 
Propensity score matching 0.41 0.18-0.89 0.030   0.49 0.22-1.05 0.067 
*Table includes univariate and multivariable logistic regression models for in-hospital mortality comparing the early 
to the nonearly treatment group. 
CI = confidence interval; other abbreviations as in Table 1. 
 
 
As a sensitivity analysis, we constructed a logistic regression model and GEE model using D2F time as a continuous 
scale (log D2F time) with an adjustment for GWTG-HF risk score. In both models, the association between log D2F 
time and in-hospital mortality remained statistically significant (OR: 1.31; 95% CI: 1.04 to 1.64; p = 0.021 for the 
logistic regression model and OR: 1.31; 95% CI: 1.01 to 1.71; p = 0.045 for the GEE model). In the propensity score 
analysis, 708 patients were matched based on the propensity score. The baseline characteristics of the cohort after 
matching are shown in Online Table 2. Among the matched patients, in-hospital mortality was, once again, lower 
in the early treatment group compared to that in the nonearly treatment group (5.9% vs. 2.5%; p = 0.038; OR: 0.41 
[0.18 to 0.89]; p value = 0.030). Furthermore, we tested the association between early treatment and 30-day 
mortality from the index hospitalization, as there was variability in the length of hospital stay. In this additional 
sensitivity analysis, early treatment was associated with a lower 30-day mortality; however, the p value did not 
reach statistical significance in multivariable logistic regression analysis after adjusting for the GWTG-HF risk score 
or in the propensity score matching analysis (Table 3).  
Figure 3 shows the association between D2F time and the probability of in-hospital mortality. Restricted cubic 
spline modeling with 4 knots was used as this model showed a better goodness-of-fit compared to that for the 
linear model and restricted 3-knot cubic spline model (p = 0.003 and p = 0.002, respectively), and showed a 
comparable goodness-of-fit to the 5-knot model (p = 0.579). The association between D2F time and predicted in-
hospital mortality was not linear, and predicted mortality steeply increased in the first approximately 100 min from 











Figure 3. Probability Plot for In-hospital Mortality  
The solid black line represents the estimated probability of in-hospital mortality, light blue shaded area is 95% 




A D2F time <60 min was observed in only one-third of patients with AHF who were hospitalized through the ED 
and treated with IV furosemide within 24 h. Patients with AHF presenting with more symptoms of congestion were 
more likely to be treated early. The association between D2F time and predicted in-hospital mortality had an 
inflection point; delaying D2F time steeply increased the mortality risk to the first approximately 100 min, but this 
effect leveled off thereafter (Central Illustration). D2F time <60 min was independently associated with a better in-
hospital outcome.  
 
D2F TIME AND PROGNOSTIC IMPLICATIONS  
The present study showed that patients treated early were more likely to arrive by ambulance and had more 
prominent symptoms of congestion, consistent with previous studies performed in the ED setting (5,14). It is not 
surprising that the delivery of AHF treatment tended to be earlier in patients with more severe symptoms. Patients 
with symptoms and signs that were less obvious might have received the appropriate diagnosis at a later time point, 









patients without a typical sign of congestion, as no historical or physical examination finding with adequately high 
sensitivity and specificity exists (15). Likewise, it is obvious that arrival by ambulance leads to early treatment given 
that these patients would be more symptomatic and/or caregivers more likely to start evaluating and treating them 
early from a logistics point of view. It should be noted that female patients tended to be treated earlier than male 
patients. A recent post hoc analysis focused on dyspnea relief in the RELAX-AHF (Relaxin for the Treatment of Acute 
Heart Failure) study showed that female AHF patients were more prone to dyspnea than men (16). 
Several retrospective studies have previously evaluated the prognostic impact of early treatment in patients with 
AHF. In ADHERE (Acute Decompensated Heart Failure National Registry), early treatment with nesiritide started in 
the ED was associated with a shorter mean hospital stay and less risk for a prolonged hospital stay (>7 days), but 
not with in-hospital mortality (17). However, as this analysis only included patients who were treated with nesiritide 
and excluded those treated with other vasodilators, the number of patients evaluated was narrowed from 105,388 
to 4,300 (4.1%); thus, the generalizability of these results to all patients with AHF is unclear. Moreover, the use of 
other intravenous drugs, such as IV diuretics, was not taken into account in ADHERE, despite the fact that more 
than 95% of the patients were treated with IV diuretics, predominantly furosemide. 
In another study using ADHERE data, an association between the time to administration of the first vasoactive 
agent and in-hospital mortality was evaluated in patients who received an IV vasoactive agent (nesiritide, 
nitroglycerin, nitroprusside, dobutamine, dopamine, or milrinone) (6). In this study, a shorter time to the first 
vasoactive agent was associated with better in-hospital mortality. This might support the results of the present 
study; however, early treatment in the previous study was defined as the use of an IV vasoactive agent ≤6 h from 
hospitalization (not ED arrival). As the time to hospitalization varies widely because many factors are involved, it is 
difficult to draw a conclusion regarding the beneficial impact of early treatment from this study. Also, similar to the 
aforementioned ADHERE study, only 25% of all initially registered patients were treated with IV vasoactive agents 
and were included in the study. Thus, selection biases might have existed and the generalizability of the findings is 
unknown. 
The ADHERE-EM (emergency module) dataset is a retrospective study evaluating patients with AHF who presented 
at the ED. The prognostic implication of the time from ED admission to the first IV HF therapy administration (loop 
diuretics, inotropes, or vasodilators, whichever was administered first) was evaluated in 6,971 patients with AHF 
age ≥65 years registered in this dataset (14). Results showed that a delay in treatment was independently 
associated with a modest but significant increase in the risk of in-hospital mortality when time to treatment was 
examined as a continuous variable. Likewise, Maisel et al. retrospectively evaluated the association between time 
to first IV furosemide and in-hospital mortality in patients with AHF hospitalized via the ED using ADHERE registry 
data (5). The authors demonstrated that in-hospital mortality increased by 2.1% per every 4 h of delay in the time 
to first IV furosemide. 
In contrast to previous studies, REALITY-AHF was a prospective study, specifically designed to examine the 
association between time to treatment and clinical outcome. One of the novel and interesting findings obtained 
from the present study was that the association between D2F time and in-hospital mortality might not be linear. In 









after approximately 100 min. These findings might support the currently recommended time window of 30 to 60 
min after ED arrival for the initiation of management for patients with AHF (8). It might also suggest that if 
physicians are more confident on the definite diagnosis of heart failure (more HF signs and symptoms), treatment 
with loop diuretics is commenced earlier and might be associated with better outcomes. Furthermore, no 
interaction between the prognostic impact of early treatment and baseline risk was found, and this treatment 
strategy might be even more effective in high-risk patients with AHF. Nonetheless, the present study and analysis 
could not determine the optimal D2F time, which needs to be evaluated in a future study. 
The present study was not designed to provide a clear explanation regarding the pathophysiological mechanism 
underlying the association between D2F time and in-hospital outcomes. However, a recent sub-study of RELAX-
AHF evaluated biomarker trajectories and showed that some organ damage markers (including high-sensitivity 
troponin) increased over time in the first 2 days in placebo groups and this increase was associated with mortality 
(18). Moreover, early treatment with serelaxin significantly attenuated the increase in high-sensitivity troponin 
within 2 days and decreased mortality. These results imply that myocardial damage is a progressive phenomenon 
in the acute phase among patients with AHF, and that early treatment mitigating this organ damage might 
consequently improve outcomes. Since we did not collect serial troponin data in the present study, this hypothesis 
should be evaluated in a future study. 
The present study findings may have an implication on both clinical practice and future clinical studies for patients 
with AHF. Previous major AHF clinical studies have not paid much attention to time to treatment and they 
consequently failed to recruit patients in the early phase of AHF (1). Although TRUE-AHF (Trial of Ularitide Efficacy 
and Safety in Acute Heart Failure) did not show positive results (19), despite recruitment of patients in the relatively 
early phase, the time from presentation to initiation of treatment appeared to be one of the most important factors 
to take into account in future clinical studies on AHF. 
STUDY LIMITATIONS. All previous analyses regarding an association between early treatment and prognosis have 
been derived from only 1 dataset (ADHERE), which retrospectively registered hospitalized patients with HF without 
a focus on the time-to-treatment concept. The present study, for the first time, prospectively focused on this 
concept in patients with AHF. Given that we used D2F time as a metric of early treatment, our study results have 
wide applicability for patients with AHF, as a substantial proportion require IV furosemide in the acute phase. 
There are several potential limitations that should be acknowledged. The small number of events in our study might 
lead to the risk of type I error and study results need to be replicated in future studies. We did not collect data 
regarding time to laboratory data or time to BNP or NT-proBNP measurement; thus, it is difficult to discriminate 
between time to diagnosis and time to treatment. Therefore, even with these data, it remains difficult to clearly 
define the exact time of diagnosis. We do not have data on the respiratory rate or cause of HF exacerbation, which 
might have an impact on outcomes. Also, an association between D2F time and long-term prognosis should be 
evaluated in a future study. In Japan, the median length of hospital stay is substantially longer than that for Western 
countries, which might affect the study results, especially for in-hospital mortality. However, in-hospital mortality 
was not substantially different between our study cohort and other registries representing American and European 









between early treatment and 30-day mortality from the time of the index admission. As differences in ED systems 
potentially exist between institutions, our study results might not apply to all institutions. We attempted to adjust 
for confounders as much as possible by using a risk score that has been validated in Japanese patients with AHF, 
and showed consistency of our results in sensitivity analyses. Nevertheless, we agree with the possibility that a 
potential unadjusted confounding could remain, such as a “confounding by indication.” Therefore, our study results 
should be interpreted carefully as there is a considerable possibility that residual confounders remain since there 
were many differences in patient background between the early and nonearly groups. It should also be noted that 
D2F time may be associated with prognosis through its association with interinstitutional differences in quality of 
care for patients with AHF in the ED rather than any direct association with prognosis, although we showed a 
consistent result in the model accounting for it. Moreover, given its observational nature, it should be noted that 
only an association, not causality, was demonstrated in the present study.  
These limitations clearly indicate that our study results are only hypothesis-generating; however, it is virtually 
impossible to randomize patients to a delayed-treatment group from an ethical point of view. As we included only 
patients hospitalized through the ED, the applicability of our study results to nonhospitalized patients is unclear. 
Additionally, we included only patients who were treated with IV furosemide within 24 h without any scientific 
basis for this time limit. However, recent studies regarding in-hospital worsening HF used 24 h from admission as 
the end of the acute phase (22,23). Moreover, changing the time-window for patient inclusion from 24 h to 48 h 












In a prospective observational study focused on the acute phase in the management of patients with AHF, we 
demonstrated that patients with AHF and prominent congestive symptoms were more likely to be treated early 
with IV furosemide. Furthermore, treatment with IV furosemide within 60 min was independently associated with 
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Supplemental Table 1. Univariate logistic regression for early treatment  
Variables B coefficient 
Standardized 
Beta 
t value P value 
Age (years) -0.002 -0.021 -0.746 0.456 
Male gender (%) 0.121 0.049 1.761 0.078 
Arrived by ambulance (%) -0.429 -0.171 -6.220 <0.001 
Symptom onset time      
≤ 6 hours Reference 
6 hours - 2 days 0.337 0.113 3.363 <0.001 
> 2 days 0.377 0.153 4.530 <0.001 
Systolic blood pressure (mmHg) -0.005 -0.144 -5.226 <0.001 
Diastolic blood pressure (mmHg) -0.005 -0.101 -3.631 <0.001 
Heart rate (bpm) -0.005 -0.117 -4.239 <0.001 
Electrocardiogram rhythm (%)     
Sinus Reference 
Atrial fibrillation 0.01 0.037 1.300 0.194 
Others 0.186 0.044 1.546 0.122 
LVEF at ED (%)     
<35% Reference 
35-50% -0.072 -0.027 -0.868 0.385 
>50% 0.124 0.046 1.514 0.130 
NYHA III/IV -0.272 -0.077 -2.682 0.007 
Medical History (%)     
Heart Failure  0.122 0.050 1.781 0.075 
Hypertension  -0.089 -0.034 -1.209 0.227 
Diabetes mellitus -0.001 0.000 -0.016 0.987 
Coronary artery disease  -0.064 -0.024 -0.863 0.388 
COPD -0.186 -0.045 -1.616 0.106 
Current or ex-smoker -0.096 -0.038 -1.368 0.172 
Physical Examination at ED (%)     
Peripheral edema  -0.248 -0.092 -3.305 <0.001 
JVD -0.441 -0.174 -6.305 <0.001 
Orthopnea -0.613 -0.240 -8.874 <0.001 
Pulmonary edema -0.398 -0.139 -5.034 <0.001 









Clinical profiles at ED (%)     
Warm - Wet Reference 
Warm - Dry 0.298 0.044 1.533 0.125 
Cold - Dry 0.096 0.026 0.895 0.371 
Cold- Wet 0.127 0.020 0.678 0.498 
Medication     
Loop diuretics 0.2 0.081 2.926 0.003 
ACE-I -0.05 -0.015 -0.543 0.587 
ARB -0.137 -0.137 -1.859 0.063 
Beta blocker 0.147 0.060 2.110 0.035 
Aldosterone blocker  0.188 0.063 2.256 0.024 
Laboratory data measured at ED     
WBC (x106/L) -2.327 -0.069 -2.494 0.013 
Hemoglobin (g/dL)   -0.004 0.008 -0.299 0.765 
ALT (IU/L) 0.00003 0.003 0.104 0.917 
AST (IU/L) 0.00005 0.005 0.164 0.869 
Creatinine (mg/dL) 0.016 0.012 0.447 0.655 
BUN (mg/dL) 0.002 0.023 0.811 0.417 
Glucose (mg/dL) -0.002 -0.123 -4.349 <0.001 
Sodium (mEq/L) -0.01 -0.039 -1.411 0.159 
CRP (mg/dL) 0.011 0.030 1.063 0.288 
BNP (pg/mL) 0.00005 0.047 1.607 0.108 
ACE-I, angiotensin converting enzyme inhibitor; ALT, aspartate aminotransferase; ARB, angiotensin II receptor 
blocker; AST, alanine aminotransferase; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic 
obstructive pulmonary disease; CRP, C-reactive protein; ED, emergency department; GWTG-HF, Get With the 
Guideline Heart Failure; JVD, jugular venous distention; LVEF, left ventricular ejection fraction; NYHA, New York 






































Age (years) 79±11 78±13  78±11 77±13 
Male gender (%) 254 (53) 471 (58)  201 (57) 201 (57) 
Arrived by ambulance (%) 349 (73) 428 (53)  241 (68) 238 (67) 
Symptom onset time       
≤ 6 hours 150 (31) 162 (20)  98 (28) 96 (27) 
6 hours - 2 days 103 (21) 179 (22)  75 (21) 84 (24) 
> 2 days 228 (47) 469 (58)  181 (51) 174 (49) 
Systolic blood pressure 
(mmHg) 
157±37 147±35  156±38 157±37 
Diastolic blood pressure 
(mmHg) 
87±26 83±25  88±26 89±27 
Heart rate (bpm) 102±29 97±28  101±29 102±27 
ECG rhythm (%)      
Sinus 286 (60) 419 (52)  198 (56) 191 (54) 
AF 155 (32) 307 (38)  121 (34) 135 (38) 
Others 40 (8) 83 (10)  35 (10) 28 (8) 
LVEF at ED (%)      
<35% 162 (37) 282 (37)  121 (36) 119 (36) 
35-50% 144 (33) 222 (29)  108 (32) 102 (31) 
>50% 135 (30) 253 (34)  104 (31) 112 (34) 
NYHA III/IV at admission 
(%) 
426 (90) 632 (85)  315 (89) 316 (89) 
Medical history (%)      
History of Heart Failure  225 (47) 428 (53)  176 (50) 163 (46) 
Hypertension  342 (71) 539 (67)  253 (72) 239 (68) 
Diabetes mellitus 180 (37) 294 (36)  132 (37) 140 (40) 
Coronary artery disease  160 (33) 240 (30)  120 (34) 106 (30) 
COPD 52 (11) 74 (9)  43 (12) 41 (12) 
Current or ex-smoker 191 (40) 305 (38)  157 (44) 143 (41) 
Physical findings at ED (%)      









JVD 326 (69) 444 (56)  232 (66) 232 (66) 
Orthopnea 361 (75) 453 (56)  255 (72) 255 (72) 
Pulmonary edema 391 (81) 586 (72)  285 (81) 297 (84) 
Rale 370 (77) 522 (65)  261 (74) 264 (75) 
Clinical profiles at ED (%)      
Warm - Dry 12 (3) 28 (4)  11 (3) 11 (3) 
Warm - Wet 391 (83) 594 (80)  283 (80) 282 (80) 
Cold - Dry 54 (11) 92 (12)  43 (12) 47 (13) 
Cold- Wet 16 (3) 27 (4)  16 (5) 14 (4) 
Medication at admission 
(%) 
     
Loop diuretics  204 (42) 437 (54)  163 (46) 160 (45) 
ACE-I 78 (16) 141 (18)  54 (15) 60 (17) 
ARB 159 (33) 243 (30)  114 (32) 102 (29) 
Beta blocker 190 (40) 341 (42)  143 (40) 135 (38) 
Aldosterone blocker  86 (18) 192 (24)  70 (20) 67 (19) 
Lab data      
WBC (/µl) 
8200 
 [6200 - 10800] 
7400 
 [5600 - 10000] 
 
8100  
[6200 - 10700] 
8400  
[6025 - 10900] 
Hemoglobin (g/dL)   11.5 [10.2 - 13.2] 11.7 [10.3 - 13.3]  11.6 [10.3 - 13.2] 11.8 [10.2 - 13.4] 
AST (IU/L) 32 [24 - 49] 31 [23 - 46]  32 [23 - 47] 31 [24 - 45] 
ALT (IU/L) 23 [14 - 35] 22 [14 - 36]  22 [14 - 34] 20 [14 - 33] 
Creatinine (mg/dL) 1.3±0.9 1.4±1.0  1.3±0.8 1.3±0.9 
BUN (mg/dL) 25 [18 - 33] 24 [18 - 35]  25 [18 - 33] 24 [17 - 33] 
Glucose (mg/dL) 181±82 159±73  172±78 176±85 
Sodium (mEq/L) 139±4 138±5  139±5 139±5 
CRP (mg/dL) 0.64 [0.20 - 2.20] 0.73 [0.25 - 2.27]  0.74 [0.23 - 2.35] 0.66 [0.24 - 2.17] 
BNP (pg/mL) 
737 
 [444 - 1333] 
746 
 [438 - 1395] 
 
752  
[449 - 1302] 
719  
[432 - 1255] 
GWTG-HF risk score  37±8 38±8  37±8 37±8 
ACE-I, angiotensin converting enzyme inhibitor; ALT, aspartate aminotransferase; ARB, angiotensin II receptor 
blocker; AST, alanine aminotransferase; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic 
obstructive pulmonary disease; CRP, C-reactive protein; ED, emergency department; GWTG-HF, Get With the 
Guideline Heart Failure; JVD, jugular venous distention; LVEF, left ventricular ejection fraction; NYHA, New York 













Supplemental Figure 1. Standardized mean difference before and after propensity score matching   
 
Standardized mean differences were below 0.1 for all baseline variables, including each component of the GWTG-
HF risk score and score itself. The C-statistics of propensity for the logistic model used to generate propensity scores 


























Acute heart failure (AHF) is a syndrome that not only involves the heart, but affects many other organs as well. The 
presence of these co-morbidities makes the pathophysiology, phenotype and treatment of this heterogeneous 
syndrome very complicated. Renal dysfunction is one of the most prevalent comorbidities with a strong association 
with clinical outcome, but a deeper understanding of the pathophysiology is lacking. Several studies that tested the 
effect of drug treatment in AHF with concomitant renal dysfunction have shown neutral results similar to other 
randomized clinical studies in patients with AHF. To better understand the pathophysiology behind renal 
dysfunction in patients with heart failure, a crucial step is to seek a successful intervention for this high-risk 
subgroup. A biomarker is a powerful tool, not only for predicting prognosis, but also for examining the biological 
pathway of the disease. Numerous studies on renal biomarkers have been conducted and most showed their strong 
association with prognosis. However, currently available renal biomarkers are not capable of providing information 
on precipitating factors of renal dysfunction in heart failure, which can vary from patient to patient. Therefore, 
attempting to use preexisting and novel biomarkers to derive such information regarding renal pathophysiology is 
clinically relevant for developing effective treatment for AHF patients, including those with concomitant renal 
dysfunction.  
 
Treatment of patients with AHF has not changed significantly for several decades, and there is no approved drug 
to adequately improve prognosis. Even though AHF has been acknowledged as a life-threatening disease that 
requires treatment as quickly as possible, surprisingly few studies have investigated the appropriate timing of 
interventions in patients with AHF. A wide variety of contemporary randomized control trials on AHF have examined 
the timing of the initial intervention, yet most of them have failed to include participants in the early phase. Given 
there are some data supporting the idea of “the earlier, the better,” it is vital to obtain more data and insights into 
this area from patient care and scientific perspectives.  
 
The primary aims of this thesis were:  
- To position the potentially novel and conventional renal biomarkers  
- To test the effectiveness of early treatment with aquaretics in AHF patients with concomitant renal 
dysfunction 
- To investigate the prognostic implication of early treatment with diuretics in patients with AHF 
 
In Chapter 2, we positioned a novel biomarker, pro-enkephalin (pro-ENK), in patient with heart failure. Pro-ENK is 
a precursor of enkephalin, which has been long-recognized and studied in the field of neuronal tissues. However, 
many studies showed (pro-) enkephalin is implicated in the cardiovascular regulation system, and one study showed 
that pro-ENK was a biomarker associated with renal function and prognosis in patients with acute myocardial 
infarction. Because the clinical value of this biomarker had not been evaluated in heart failure patients, we 









well-evaluated using 131I-Hippuran and 125I-Iothalamate to evaluate its association with renal function. In addition, 
to elucidate the prognostic predictability of pro-ENK in patients with AHF, the levels of pro-ENK were evaluated in 
1589 patients in the PROTECT dataset (AHF cohort). In a renal mechanistic cohort, we found pro-ENK levels to be 
strongly associated with glomerular function and measured (not estimated) glomerular function using radioactive 
tracers was the most powerful predictor of pro-ENK levels. In contrast, pro-ENK was not associated with urinary 
tubular markers (NAG, NGAL, and KIM-1). In the AHF cohort, again, high pro-ENK levels were strongly associated 
with low glomerular markers (creatinine and blood urea nitrogen) and worse outcomes. However, its prognostic 
predictability was not retained after adjusting for pre-existing renal biomarkers, including creatinine and BUN. 
Altogether, we positioned pro-ENK as a glomerular marker rather than a tubular marker in patients with heart 
failure. Pro-ENK was associated with a worse prognosis in patients with AHF; however, its additive prognostic 
information to pre-existing renal markers is limited.  
 
In Chapter 3, we attempted to define the normal range of the blood urea nitrogen (BUN)/creatinine ratio in the 
general population (PREVEND cohort), and the prognostic value of being out of normal range in patients with AHF. 
Like creatinine, BUN is a readily available renal biomarker in daily clinical practice. From a metabolic point of view, 
BUN is similar to creatinine in that it is freely filtrated at the glomerulus and, therefore, strongly associated with 
renal function, particularly with glomerular function. However, contrary to the fact that creatinine is not 
reabsorbed in tubules, approximately 40-50% of BUN is reabsorbed in the tubules and this process is directly and 
indirectly handled by neurohormonal activity including the renin-angiotensin-aldosterone system, sympathetic 
nerves, and arginine-vasopressin system. This difference forms the pathophysiological basis of the BUN/creatinine 
ratio as a metric of neurohormonal activity in patients with heart failure. There have been many studies that have 
showed the association between high BUN/creatinine ratio and poor prognosis in patients with heart failure, but 
no study has investigated the normal range of BUN/creatinine ratio. We sought to define the normal range of 
BUN/creatinine ratio using data derived from the general population without overt cardiovascular comorbidities 
and to find its prognostic meaning in patients with AHF. In the general population, we found that the 
BUN/creatinine ratio increased with age, and significantly more in females compared with males. Moreover, the 
BUN/creatinine ratio varied widely in the general population, which may imply that using a reference range might 
be useful to define patients with a high BUN/creatinine ratio. Patients with a higher than normal range 
BUN/creatinine ratio are associated with indices that indicate a highly activated neurohormonal system. A higher 
than normal range BUN/creatinine ratio among patients was associated with worse outcomes compared with 
patients within normal range, and this association remained even after adjusting for pre-existing renal biomarkers, 
including creatinine and BUN. This finding suggests that to know if BUN/creatinine ratio is out of normal range may 
provide us with pathophysiological information on the renal function in AHF patients that cannot be provided 
otherwise. However, this hypothesis should be tested in a study that has clearer pathophysiological information on 
the background of renal dysfunction in patients with AHF.  
 









renal dysfunction in Chapters 4, 5, and 6. 
 
In Chapter 4, we described the rationale for our study. Among AHF patients, those with renal dysfunction are at 
especially high-risk of poor outcome. One of the clinical concerns of this subgroup is diuretic resistance, and 
subsequent unsatisfactory decongestion, which has shown to be strongly associated with a poor prognosis. 
Tolvaptan is an emerging new class of diuretics that causes electrolyte-free water excretion and yields urine output 
in a different form. Tolvaptan’s clinical effectiveness was tested in a large-scale, double-blinded, randomized clinical 
trial, EVEREST, which revealed that tolvaptan was significantly more effective in causing decongestion in the short-
term, but found no mid-term prognostic benefit compared to placebo. However, EVEREST did not focus on patients 
with renal dysfunction. More importantly, EVEREST enrolled participants relatively late after admission, similar to 
other contemporary AHF studies, which leads to Chapter 7 in which tolvaptan’s clinical implications are more 
explicitly discussed. Therefore, we set out to test the hypothesis that early treatment, within 6 hours of admission, 
with tolvaptan can more effectively and safely treat AHF patients with renal dysfunction compared to conventional 
treatment. We designed a multicenter, open-label, randomized clinical trial, AQUAMARINE, to test this hypothesis 
and enrolled 220 Japanese AHF patients with renal dysfunction defined as an estimated GFR 15 to 60 mL/min/1.73 
m2. The primary endpoint was urine output achieved within 48 hours of randomization.  
 
The main findings of the AQUAMARINE study are presented in Chapter 5. Two-hundred twenty AHF patients whose 
estimated GFR below 60 mL/min/1.73 m2 were enrolled and randomized to either the tolvaptan treatment group 
or conventional treatment group. Patients in the tolvaptan group were treated with tolvaptan add-on therapy (15 
mg add-on therapy once daily for 2 days). Median time to randomization from admission was 1 hour, and 41.4% of 
patients were randomized before admission at either the emergency department or clinic. After three patients 
were excluded, 217 patients were included in the analysis. The tolvaptan group yielded significantly more urine 
output compared to the conventional group (6464 mL vs. 4997 mL, P <0.001). Regarding secondary outcomes, we 
observed a significantly greater reduction in body weight, more frequent dyspnea relief at all time points within 48 
hours, except 6 hours after randomization in favor of the tolvaptan group, even though less amount of furosemide 
was used in the tolvaptan group compared to the conventional group. On the other hand, incidence of worsening 
renal function (WRF), which was one of the prespecified secondary endpoints and defined as ≥0.3 mg/dL increase 
in creatinine from baseline, did not significantly differ between groups. Likewise, there was no significant difference 
in the trajectory of creatinine measured at several prespecified time points (6, 12, 24, and 48 hours of 
randomization). Furthermore, no differences were observed between the tolvaptan group and conventional group 
in incidence of any adverse events and combined endpoint of all-cause death and heart failure readmission within 
90 days of randomization. Although our study results should be interpreted cautiously, due to its open-label study 
design, successful very early patients’ enrollment/randomization and subsequent positive results in the primary 
endpoint might suggest that early use of tolvaptan could be an option for AHF patients with renal dysfunction.  
 









AQUAMARINE study dataset. In this analysis, diuretic responses were evaluated for each patient as the change in 
body weight from baseline to 48 hours and net fluid loss within 48 hours per 40 mg intravenous furosemide-
equivalent dose. We found that patients with a poor diuretic response were less likely to have dyspnea relief within 
48 hours and were more likely to experience WRF defined as a ≥0.3 mg/dL increase in creatinine from baseline. 
Tolvaptan was independently associated with a good diuretic response in both definitions. Also, we found that the 
diuretic response in the conventional groups was relatively better than our expectation given that only patients 
whose estimated GFR was below 60 mL/min/1.73 m2 were included in AQUAMARINE study. There are several 
possible explanations for this finding, including early treatment contributes to a better diuretic response; however, 
this hypothesis needs to be evaluated in another study that is more focused on this topic. Together with Chapter 
5, we showed the effectiveness of early treatment with tolvaptan in AHF patients with renal dysfunction in terms 
of decongestion. However, once again, these findings should be interpreted cautiously as our study tested a small 
sample size and, more importantly, in an open-label fashion.  
 
Clinical implications of the concept “time to treatment” in patients with AHF was directly evaluated in Chapter 7. 
Although some studies have already suggested a favorable prognostic impact of early treatment in patients with 
AHF, all were retrospective studies using the same large, but retrospective registry dataset (ADHERE registry). We 
conducted a multicenter prospective registry, REALITY-AHF, primarily focusing on the relationship between early 
treatment and prognosis in AHF patients hospitalized through the emergency department with 20 participating 
institutions in Japan. We analyzed 1291 AHF patient who were treated with intravenous furosemide within 24 hours 
of emergency department arrival. Door-to-furosemide time was defined as the time from patient arrival at the 
emergency department to the first intravenous furosemide injection and prospectively collected. About one third 
of patients were treated within 60 minutes, and this was associated with lower in-hospital mortality compared to 
those who were treated later than 60 minutes with intravenous furosemide. Moreover, we found a non-linear 
association between door-to-furosemide time and in-hospital mortality; predicted in-hospital mortality steeply 
increased in the first approximately 100 minutes from patient arrival in the emergency department and leveled off 
afterwards. This prospectively obtained data give us, for the first time, a clear basis for advocating early treatment 
with diuretics in AHF patients who require decongestion from a prognostic point of view.  
 
Future perspectives  
Cardiorenal biomarkers in AHF 
Renal dysfunction is one of the most common comorbidities in patients with AHF and its association with worse 
outcomes is robustly proven. Biomarker studies have played a pivotal role in the progress towards understanding 
this association. However, the understanding of the pathophysiological background of renal dysfunction in heart 











First, we do not have a renal biomarker capable of capturing renal function accurately and timely in patients with 
AHF. Conventionally, GFR has been used to explain the majority of renal function and has played the most important 
role. The gold standard method of measuring GFR is using plasma or urinary clearance of an exogenous filtration 
marker, such as inulin, or measuring with radioisotope or iothalamate methods. However, since these are 
realistically not available in daily clinical practice, estimated GFR from serum creatinine is generally used in the 
clinical practice setting to evaluate glomerular function. Several studies have validated the accuracy of creatinine-
based GFR in the general population and some modified equations have been developed for better estimating GFR; 
however, few studies have validated this estimation method in patients with heart failure. In addition, it should be 
noted that no study has validated creatinine-based estimated GFR in patients with AHF. Given that creatinine is not 
a suitable biomarker, especially in a non-stable setting, as it is unable to reflect a rapidly changing GFR and starts 
elevating when at least at 50% of GFR loss; the accuracy of creatinine-based estimated GFR in patients with acute 
rather than chronic HF is unclear. Based on these reasons, creatinine might not be an ideal biomarker to evaluate 
glomerular function in patients with AHF.  
 
Second, we do not have a renal biomarker that provides pathophysiological information on the cause of renal 
dysfunction in patients with heart failure. Currently, we are able to recognize only the consequence, but not the 
causes, of deteriorating renal function using biomarkers. This important limitation has been reinforced by many 
studies, which have shown that increased creatinine is not always translated into poor prognosis as once was 
thought. Clinical circumstances surrounding an increase in creatinine is important to understand if it is likely to 
accompany subsequent unfavorable outcomes. For instance, Metra et al. showed that WRF results in inadequate 
decongestion during hospitalization, but not that WRF with adequate decongestion leads to a worse prognosis 
compared to those without WRF. Also, WRF caused by administering an angiotensin converting enzyme inhibitor 
in patients with heart failure with reduced ejection fraction (HFrEF) is not associated with better outcomes. On the 
other hand, an increase in creatinine occurring after introducing an ARB was associated with worse outcomes in 
patients with heart failure who have a preserved ejection fraction (HFpEF). The difference in the prognostic impact 
of worsening renal function between HFrEF and HFpEF was validated in a recent meta-analysis. These “conditional” 
associations between WRF and prognosis suggest the importance of the cause of an increase in creatinine rather 
than the increase itself, and the phenotyping of WRF, which might be enabled with renal biomarkers capable of 
providing renal pathophysiological information.  
 
Finally, we do not have a renal biomarker encompassing all functions of the whole kidney. Several studies have 
underscored the prognostic importance of tubular damage measured by several tubular markers (e.g., NGAL, KIM-
1, and beta-2-microglobulin) in patients with acute heart failure. These tubular markers have prognostic predictive 
ability independent from glomerular markers. This implies we should integrate information on glomerular function 
with information on tubular damage to better comprehend renal function. It should also be noted that there are 
biomarkers available for evaluating tubular “dys”-function, but the definition and gold standard measurement of 









glomerular pathophysiology and allows us to comprehend the whole picture of renal function, will be welcome.  
 
There is no doubt that biomarkers have been contributing to the diagnosis, risk stratification, and understanding 
of the underlying pathophysiology of heart failure. On the other hand, it is fair to say very few new and old 
biomarkers have changed our daily clinical practice when it comes to treatment/intervention as no clear answer 
has been shown to have clinical implications in biomarker-guided therapy trials. To better understand and manage 
AHF patients with concomitant renal dysfunction, it is essential to keep looking for the biomarker that describes 
much about the “kidney” and not the “prognosis” in patients with heart failure. To speak of extremes, we do not 
know if we can treat AHF patient better with biomarkers even compared to “zero-biomarker” treatment. In fact, 
most of the recommended acute-phase treatments for patients with AHF were based on physical findings or simple 
vital signs but not on biomarkers at the moment. We might also have to rethink of cost-effectiveness of utilizing 
biomarker in management of AHF patients as some biomarkers are costly. 
Another general question that remains regarding biomarker research in heart failure is that of causality. Most 
previous studies that evaluated the significance of biomarkers have showed only an association rather than 
causality. Therefore the next critical step we need to take in the use and research on biomarkers is to consider the 
presence or absence of causality. From a biological point of view, each biomarker is implicated in several biological 
pathways and can be influenced by many factors which also impact outcomes. This makes it very difficult to test a 
pure association between biomarkers and outcomes of interest, even though many sophisticated statistical 
analyses are used to adjust for confounding factors. Recent progress in genetic analyses and genome-wide 
association studies now enable us to infer causality between biomarkers and outcomes, including prognosis. This 
process is quite important in many aspects. The biomarker can be a very strong surrogate marker for testing 
treatment strategies or the development of new drugs if the causality between the biomarker and the outcome is 
in the direction of biomarker to outcome. Considering some recent studies have shown the lack of (or very little, 
at least) causality between some biomarkers and outcomes which has been proven by many observational studies, 
a similar approach should also be taken for renal biomarkers in HF patients. Mendelian randomization, which is 
one of the means to allow us to reason causality, has been increasingly used in medical research; however, there is 
no study applying this novel, time- and cost-effective approach to the heart failure population. Narrowing down 
only the biomarkers that have a causal association with clinically relevant outcomes should aid us in accelerating 
biomarker research in the field of heart failure.  
 
Optimal timing for treatment in AHF  
Heart failure is a progressive disease, and symptoms change and fluctuate overtime. Even if the patient’s condition 
has been stable for years, it can abruptly collapse and decompensate within a couple of minutes. Therefore, it is 
very natural to say that care providers need to provide the right treatment to the right patients at the right time; 
however, most of the AHF clinical randomized studies, which have been performed in the last decades, have paid 
attention mostly to the means of intervention and not much on timing and patient selection. The notion “the earlier 









several retrospective studies have shown the same association between time to treatment and several outcomes. 
Nonetheless, there has been no study focusing on this timing of treatment in AHF patients. In this thesis, we 
confirmed the favorable association between early treatment and outcomes in AHF patients, which encourages us 
to take, more seriously, into account this notion in both daily clinical practice and in designing clinical studies. To 
data, a few AHF randomized control trials successfully enrolled patients relatively early. In the RELAX-AHF, mean 
time from admission to randomization was 7.9 hours and serelaxin did not affect the composite of heart failure 
hospitalization or death through 60 days. Treatment with serelaxin was associated with lower 180 days all-cause 
and cardiovascular mortality; however, this finding was not replicated in RELAX-AHF-2 study. In the TRUE-AHF study, 
all patients were allocated to either ularitide or placebo in a median of 6.1 hours after the initial clinical evaluation 
and showed a neutral impact on prognosis. These results might contradict the idea we proposed; however, there 
are many alternative explanations. Both serelaxin and ularitide was shown to reduce blood pressure and BNP in 
the study period, but it does not necessarily mean its associated with a better prognosis. It should be noted that 
the neutral prognostic impact of this early treatment with these AHF drugs can be generalized providing that these 
are the drug capable of improving prognosis. However, thus far, no study has shown a favorable impact of any kind 
of vasodilator on prognosis, and it is fair to say the results of RELAX-AHF and TRUE-AHF did not fully address the 
hypothesis. In Chapter 7, we suggested that the possible optimal timing for starting treatment might be much 
earlier than 6 hours from the time of patient admission. This result supports our speculation proposed in Chapter 
6; we inferred that one of the reasons for observing an unexpectedly good diuretic response in the AQUAMARINE 
cohort might be the early treatment provided (i.e., a median of 2.1 hours from the time of patient evaluation). 
Alternatively, these results raise additional questions, especially about the pathophysiological background of its 
beneficial effect and “optimal” timing for early intervention in patients with decompensated heart failure. One 
possible explanation for favorable prognostic impact of early treatment with diuretics is that early treatment might 
mitigate organ damage progressing in acute phase and consequently improve outcomes. However, at the same 
time, it should be noted that patients with early treatment showed significantly different patient characteristics 
compared to those without, and this difference could contribute to difference in prognosis. As the worsening and 
improving of heart failure symptoms are not clearly distinguishable statuses, and are rather sequential in nature, 
an approach that allows us to intervene with the patient that is about to become decompensated might be more 
optimal. Indeed, a recent study, the CHAMPION trial, using a pulmonary artery pressure monitoring device showed 
results compatible with our hypothesis. Overall, although the data on the timing of treatment in patients with acute 
heart failure consistently show a significant influence on outcomes, including prognosis, the optimal timing and 
means of intervention remain to be clarified in future studies.         
 
In conclusion, renal biomarkers have helped us identify AHF patients at high risk; however, their utility in optimizing 
treatment for AHF patients with concomitant renal dysfunction has yet to be realized. To make this a reality, it is 
important to not only keep looking for a novel renal biomarker, but also to seek an effective incorporation of pre-
existing renal biomarkers in clinical practice. The same is true for interventions in patients with AHF. Finding a better 









drugs have been examined in randomized clinical trials; however, most of the trials resulted in neutral results, yet 
much has been learned in the process. Hopefully, this thesis will serve to help researchers to consider how the 
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